

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C12N 9/54, C11D 3/386</b>		A1	(11) International Publication Number: <b>WO 99/27082</b> (43) International Publication Date: <b>3 June 1999 (03.06.99)</b>
(21) International Application Number: <b>PCT/DK98/00496</b> (22) International Filing Date: <b>17 November 1998 (17.11.98)</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: <b>1332/97 21 November 1997 (21.11.97) DK</b>		Published <i>With international search report.</i>	
(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé, DK-2880 Bagsværd (DK).			
(72) Inventors: HANSEN, Peter, Kamp; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). BAUDITZ, Peter; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK). MIKKELSEN, Frank; Novo Nordisk A/S, Novo Allé, DK-2880 Bagsværd (DK).			
(74) Agent: NOVO NORDISK A/S; Novo Allé, DK-2880 Bagsværd (DK).			
(54) Title: PROTEASE VARIANTS AND COMPOSITIONS			
(57) Abstract			
A protease subtilase enzyme, characterized by an insertion in at least one active site loop. The enzymes exhibit improved wash performance in a detergent in comparison to its parent enzyme if it is a subtilase variant.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		

TITLE: PROTEASE VARIANTS AND COMPOSITIONSTECHNICAL FIELD

This invention relates to novel mutant protease enzymes or enzyme variants, comprising insertions in one or more active site loops, useful in formulating detergent compositions and exhibiting improved wash performance in detergents; cleaning and detergent compositions containing said enzymes; mutated genes coding for the expression of said enzymes when inserted into a suitable host cell or organism; and such host cells transformed therewith and capable of expressing said enzyme variants.

BACKGROUND OF THE INVENTION

15 In the detergent industry enzymes have for more than 30 years been implemented in washing formulations. Enzymes used in such formulations comprise proteases, lipases, amylases, cellulases, as well as other enzymes, or mixtures thereof. Commercially most important enzymes are proteases.

20 An increasing number of commercially used proteases are protein engineered variants of naturally occurring wild type proteases, e.g. DURAZYM® (Novo Nordisk A/S), RELEASE® (Novo Nordisk A/S), MAXAPEM® (Gist-Brocades N.V.), PURAFECT (Genencor International, Inc.).

25 Further a number of protease variants are described in the art, such as in EP 130756 (GENENTECH) (corresponding to US Reissue Patent No. 34,606 (GENENCOR)); EP 214435 (HENKEL); WO 87/04461 (AMGEN); WO 87/05050 (GENEX); EP 260105 (GENENCOR); Thomas, Russell, and Fersht (1985) *Nature* 318 375-376; Thomas, Russell, and Fersht (1987) *J. Mol. Biol.* 193 803-813; Russel and Fersht *Nature* 328 496-500 (1987); WO 88/08028 (Genex); WO 88/08033 (Amgen); WO 95/27049 (SOLVAY S.A.); WO 95/30011 (PROCTER & GAMBLE COMPANY); WO 95/30010 (PROCTER & GAMBLE COMPANY); WO 95/29979 (PROCTER & GAMBLE COMPANY); US 5,543,302 (SOLVAY S.A.); EP 251 446 (GENENCOR); WO 89/06279 (NOVO NORDISK A/S); WO 91/00345 (NOVO NORDISK A/S); EP 525 610 A1 (SOLVAY); and WO 94/02618 (GIST-BROCADES N.V.).

However, even though a number of useful protease variants have been described, there is still a need for new improved proteases or protease variants for a number of industrial uses.

5 Therefore, an object of the present invention, is to provide improved proteases or protein engineered protease variants, especially for use in the detergent industry.

#### SUMMARY OF THE INVENTION

10 The present inventors have identified that it is possible to construct variants of BLSAVI (Savinase®), having improved wash performance in detergent, as compared to the parent wildtype BLSAVI, by introducing at least one insertion in at least one of the active site loops in said BLSAVI.

15 It is predicted that it will be possible to make similar variants in other subtilases, which are similar to BLSAVI.

Further it is predicted that it is possible to isolate from nature and identify naturally occurring parent or wildtype subtilases, having improved wash performance in a 20 detergent, as compared to BLSAVI, by specifically screening for such parent wildtype subtilases comprising at least one active site loop, which is longer than the corresponding active site loop in BLSAVI.

Accordingly, in a first aspect the invention relates to 25 an isolated subtilase enzyme, having improved wash performance in a detergent, as compared to BLSAVI, having an amino acid sequence which is at least 40 % identical to the amino acid sequence of the mature BLSAVI, and characterized by that at least one of the active site loops, in said isolated 30 subtilase, is longer than the corresponding active site loop in BLSAVI, whereby such active site loops regions, in said isolated subtilase, is having the minimum amino acid length as specified from the group below comprising:

- (a) the region (both of the end amino acids included) between amino acid residue from 33 to 43 is at least 11 amino acid long (i.e. at least one amino acid insertion, as compared to BLSAVI);
- 5 (b) the region (both of the end amino acids included) between amino acid residue 95 to 103 is at least 9 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI);
- (c) the region (both of the end amino acids included)
- 10 between amino acid residue 125 to 132 is at least 8 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI);
- (d) the region (both of the end amino acids included) between amino acid residue 153 to 173 is at least 21 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI);
- 15 (e) the region (both of the end amino acids included) between amino acid residue 181 to 195 is at least 15 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI);
- 20 (f) the region (both of the end amino acids included) between amino acid residue 202 to 204 is at least 3 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI); and
- 25 (g) the region (both of the end amino acids included) between amino acid residue 218 to 219 is at least 3 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI).

30 In a second aspect the invention relates to an isolated DNA sequence encoding a subtilase variant of the invention.

In a third aspect the invention relates to an expression vector comprising an isolated DNA sequence encoding a subtilase variant of the invention.

35 In a fourth aspect the invention relates to a microbial host cell transformed with an expression vector according to the fourth aspect.

In a further aspect the invention relates to the production of the subtilisin enzymes of the invention by inserting an expression vector according to the fourth aspect into a suitable microbial host, cultivating the host to express the desired subtilase enzyme, and recovering the enzyme product.

Further the invention relates to a composition comprising a subtilase variant of the invention.

Even further the invention relates to the use of the mutant enzymes for a number of industrial relevant uses, in particular for use in cleaning compositions and cleaning compositions comprising the mutant enzymes, especially detergent compositions comprising the mutant subtilisin enzymes.

15

#### DEFINITIONS

Prior to discussing this invention in further detail, the following term will first be defined.

#### 20 NOMENCLATURE OF AMINO ACIDS

A	=	Ala	=	Alanine
V	=	Val	=	Valine
L	=	Leu	=	Leucine
I	=	Ile	=	Isoleucine
25 P	=	Pro	=	Proline
F	=	Phe	=	Phenylalanine
W	=	Trp	=	Tryptophan
M	=	Met	=	Methionine
G	=	Gly	=	Glycine
30 S	=	Ser	=	Serine
T	=	Thr	=	Threonine
C	=	Cys	=	Cysteine
Y	=	Tyr	=	Tyrosine
N	=	Asn	=	Asparagine
35 Q	=	Gln	=	Glutamine
D	=	Asp	=	Aspartic Acid
E	=	Glu	=	Glutamic Acid
K	=	Lys	=	Lysine

R = Arg = Arginine  
H = His = Histidine  
X = Xaa = Any amino acid

5 NOMENCLATURE OF NUCLEIC ACIDS

A = Adenine  
G = Guanine  
C = Cytosine  
T = Thymine (only in DNA)  
10 U = Uracil (only in RNA)

NOMENCLATURE OF VARIANTS

In describing the various enzyme variants produced or contemplated according to the invention, the following nomenclatures have been adapted for ease of reference:

Original amino acid(s) position(s) substituted amino acid(s)

In the case when the original amino acid residue may be 20 any amino acid residue, a short hand notation may at times be used indicating only the position and substituted amino acid,

Position substituted amino acid

25 Such a notation is particular relevant in connection with modification(s) in homologous subtilases (*vide infra*).

Similarly when the identity of the substituting amino acid residue(s) is immaterial,

30

Original amino acid position

When both the original amino acid(s) and substituted amino acid(s) may comprise any amino acid, then only the 35 position(s) is indicated, e.g.: 170.

When the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s),

then the selected amino acids are indicated inside brackets {}.

Original amino acid position {substituted amino acid<sub>1</sub>, ...,  
5 substituted amino acid<sub>n</sub>}

For specific variants the specific three or one letter codes are used, including the codes Xaa and X to indicate any amino acid residue.

10

#### SUBSTITUTIONS:

The substitution of Glutamic acid for glycine in position 195 is designated as:

Gly195Glu                  or    G195E

15 or the substitution of any amino acid residue acid for glycine in position 195 is designated as:

Glu195Xaa                  or G195X

or

Glu195                  or G195

20

The substitution of serine for any amino acid residue in position 170 would thus be designated

Xaa170Ser                  or X170S.

or

25                  170Ser                  or 170S

Such a notation is particular relevant in connection with modification(s) in homologous subtilases (*vide infra*).

170Ser is thus meant to comprise e.g. both a Lys170Ser modification in BASBPN and Arg170Ser modification in BLAVI. See figure 1 in relation to these examples.

For a modification where the original amino acid(s) and/or substituted amino acid(s) may comprise more than one, but not all amino acid(s), the substitution of glycine, 35 alanine, serine or threonine for arginine in position 170 would be indicated by

Arg170{Gly, Ala, Ser, Thr}                  or R170{G, A, S, T}

to indicate the variants  
R170G, R170A, R170S, and R170T.

DELETIONS:

5 A deletion of glycine in position 195 will be indicated by:

Gly195\* or G195\*

Correspondingly the deletion of more than one amino acid residue, such as the deletion of glycine and leucine in 10 positions 195 and 196 will be designated

Gly195\*+Leu196\* or G195\*+L196\*

INSERTIONS:

The insertion of an additional amino acid residue such 15 as e.g. a lysine after G195 is :

Gly195GlyLys or G195GK; or

when more than one amino acid residue is inserted, such as e.g. a Lys, Ala and Ser after G195 this is :

20 Gly195GlyLysAlaSer or G195GKAS

In such cases the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino 25 acid residue(s). In the above example the sequences 194 to 196 would thus be:

194 195 196

BLSAVI A - G - L

194 195 195a 195b 195c 196

30 Variant A - G - K - A - S - L

In cases where an amino acid residue identical to the existing amino acid residue is inserted it is clear that a kind of degeneracy in the nomenclature arises. If for example 35 a glycine is inserted after the glycine in the above example this would be indicated by G195GG. The same actual change could just as well be indicated as A194AG for the change from

194 195 196

BLSAVI        A - G - L  
to  
                194 195 195a 196  
Variant        A - G - G - L  
5                194 194a 195 196

Such instances will be apparent to the skilled person,  
and the indication G195GG and corresponding indications for  
this type of insertions are thus meant to comprise such  
10 equivalent degenerate indications.

FILLING A GAP:

Where a deletion in an enzyme exists in comparison to  
the subtilisin sequence used for the numbering, an insertion  
15 in such a position is indicated as:

\*36Asp        or     \*36D

for the insertion of an aspartic acid in position 36

MULTIPLE MODIFICATIONS

20              Variants comprising multiple modifications are separated  
by pluses, e.g.:

Arg170Tyr + Gly195Glu or R170Y+G195E  
representing modifications in positions 170 and 195  
substituting tyrosine and glutamic acid for arginine and  
25 glycine, respectively.

or e.g. Tyr167{Gly,Ala,Ser,Thr}+Arg170{Gly,Ala,Ser,Thr}  
designates the variants

Tyr167Gly+Arg170Gly,        Tyr167Gly+Arg170Ala,  
Tyr167Gly+Arg170Ser,        Tyr167Gly+Arg170Thr,  
30              Tyr167Ala+Arg170Gly,        Tyr167Ala+Arg170Ala,  
Tyr167Ala+Arg170Ser,        Tyr167Ala+Arg170Thr,  
Tyr167Ser+Arg170Gly,        Tyr167Ser+Arg170Ala,  
Tyr167Ser+Arg170Ser,        Tyr167Ser+Arg170Thr,  
Tyr167Thr+Arg170Gly,        Tyr167Thr+Arg170Ala,  
35              Tyr167Thr+Arg170Ser,        and Tyr167Thr+Arg170Thr.

This nomenclature is particular relevant relating to  
modifications aimed at substituting, replacing, inserting or  
deleting amino acid residues having specific common

properties, such as residues of positive charge (K, R, H), negative charge (D, E), or conservative amino acid modification(s) of e.g.

Tyr167{Gly, Ala, Ser, Thr}+Arg170{Gly, Ala, Ser, Thr}, which signifies substituting a small amino acid for another small amino acid. See section "Detailed description of the invention" for further details.

### PROTEASES

10 Enzymes cleaving the amide linkages in protein substrates are classified as proteases, or (interchangeably) peptidases (see Walsh, 1979, *Enzymatic Reaction Mechanisms*. W.H. Freeman and Company, San Francisco, Chapter 3).

### 15 NUMBERING OF AMINO ACID POSITIONS/RESIDUES

Unless otherwise stated the amino acid numbering used herein correspond to that of the subtilase BPN' (BASBPN) sequence. For further description of the BPN' sequence see Siezen et al., *Protein Engng.* 4 (1991) 719-737 and Figure 1.

20

### SERINE PROTEASES

A serine protease is an enzyme which catalyzes the hydrolysis of peptide bonds, and in which there is an essential serine residue at the active site (White, Handler and 25 Smith, 1973 "Principles of Biochemistry," Fifth Edition, McGraw-Hill Book Company, NY, pp. 271-272).

The bacterial serine proteases have molecular weights in the 20,000 to 45,000 Dalton range. They are inhibited by diisopropylfluorophosphate. They hydrolyze simple terminal 30 esters and are similar in activity to eukaryotic chymotrypsin, also a serine protease. A more narrow term, alkaline protease, covering a sub-group, reflects the high pH optimum of some of the serine proteases, from pH 9.0 to 11.0 (for review, see Priest (1977) *Bacteriological Rev.* 41 711-753).

SUBTILASES

A sub-group of the serine proteases tentatively designated subtilases has been proposed by Siezen et al., *Protein Engng.* 4 (1991) 719-737. They are defined by homology analysis of more than 40 amino acid sequences of serine proteases previously referred to as subtilisin-like proteases. A subtilisin was previously defined as a serine protease produced by Gram-positive bacteria or fungi, and according to Siezen et al. now is a subgroup of the subtilases. A wide variety of subtilases have been identified, and the amino acid sequence of a number of subtilases have been determined. For a more detailed description of such subtilases and their amino acid sequences reference is made to Siezen et al. and figure 1 herein.

One subgroup of the subtilases, I-S1, comprises the "classical" subtilisins, such as subtilisin 168, subtilisin BPN<sup>®</sup>, subtilisin Carlsberg (ALCALASE<sup>®</sup>, NOVO NORDISK A/S), and subtilisin DY.

A further subgroup of the subtilases I-S2, is recognized by Siezen et al. (*supra*). Sub-group I-S2 proteases are described as highly alkaline subtilisins and comprise enzymes such as subtilisin PB92 (MAXACAL<sup>®</sup>, Gist-Brocades NV), subtilisin 309 (SAVINASE<sup>®</sup>, NOVO NORDISK A/S), subtilisin 147 (ESPERASE<sup>®</sup>, NOVO NORDISK A/S), and alkaline elastase YaB.

25

"SAVINASE®"

SAVINASE<sup>®</sup> is marketed by NOVO NORDISK A/S. It is subtilisin 309 from *B. Lentus* and differs from BABP92 only in one position (N87S, see figure 1 herein). SAVINASE<sup>®</sup> has the amino acid sequence designated BLSEAVI (see figure 1 herein).

PARENT SUBTILASE

The term "parent subtilase" is a subtilase defined according to Siezen et al. (*Protein Engineering* 4:719-737 (1991)). For further details see description of "SUBTILASES" immediately above. A parent subtilase may also be a subtilase isolated from a natural source, wherein subsequent

modification have been made while retaining the characteristic of a subtilase.

Alternatively the term "parent subtilase" may be termed "wild-type subtilase".

5

#### MODIFICATION(S) OF A SUBTILASE VARIANT

The term "modification(s)" used in connection with modification(s) of a subtilase variant as discussed herein is defined to include chemical modification as well as genetic manipulation. The modification(s) can be by substitution, deletion and/or insertions in or at the amino acid(s) of interest.

#### SUBTILASE VARIANT

15 In the context of this invention, the term subtilase variant or mutated subtilase means a subtilase that has been produced by an organism which is expressing a mutant gene derived from a parent microorganism which possessed an original or parent gene and which produced a corresponding 20 parent enzyme, the parent gene having been mutated in order to produce the mutant gene from which said mutated subtilase protease is produced when expressed in a suitable host.

#### HOMOLOGOUS SUBTILASE SEQUENCES

25 Specific active site loop regions, and amino acid insertions in said loops of the subtilase SAVINASE® are identified for modification herein to obtain a subtilase variant of the invention.

However, the invention is not limited to modifications 30 of this particular subtilase, but extend to other parent (wild-type) subtilases, which have a homologous primary structure to that of SAVINASE®.

In order to identify other homologous subtilases, within the scope of this invention, an alignment of said subtilase(s) 35 to a group of previously aligned subtilases is performed keeping the previous alignment constant. A comparison to 18 highly conserved residues in subtilases is performed. The 18

highly conserved residues are shown in table I (see Siezen et al. for further details relating to said conserved residues).

Table I

<u>18 highly conserved residues in subtilases</u>		
	Position:	Conserved residue
	23	G
	32	D
	34	G
10	39	H
	64	H
	65	G
	66	T
	70	G
15	83	G
	125	S
	127	G
	146	G
	154	G
20	155	N
	219	G
	220	T
	221	S
	225	P

25

After aligning allowing for necessary insertions and deletions in order to maintain the alignment suitable homologous active site loop regions are identified. Said homologous residues can then be modified according to the 30 invention.

Using the CLUSTALW (version 1.7, June 1997) computer alignment program (Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) Nucleic Acids Research, 22:4673-4680.), using default alignment parameters, alignment of a given subtilase 35 to a group of previously aligned subtilases is achieved using the *Profile alignments* option in the program. For a given subtilase to be within the scope of the invention, preferably 100% of the 18 highly conserved residues should be conserved.

However, alignment of greater than or equal to 17 out of the 18 residues, or as little as 16 of said conserved residues is also adequate to identify homologous residues. Conservation of the, in subtilases, catalytic triad Asp32/His64/Ser221 should be maintained.

An alignment of 10 subtilases as defined is shown in Fig. 1.

Further in said process to identify a homologous parent (wild-type) subtilase within the scope of the invention, the 10 18 conserved residues above relates to the parent (wild-type) primary sequence of said homologous parent subtilase. In other words, if a parent subtilase has been modified in any of said 18 conserved residues above, it is the original parent wild-type sequence in said 18 conserved residues, which determines 15 whether or not both the original parent subtilase and a possible variant of said parent subtilase, which is modified in any of said 18 conserved residues above, is a homologous subtilase within the scope of the present invention.

Based on this description it is routine for a person skilled in the art to identify suitable homologous subtilases and corresponding homologous active site loop regions, which can be modified according to the invention.

#### WASH PERFORMANCE

25 The ability of an enzyme to catalyze the degradation of various naturally occurring substrates present on the objects to be cleaned during e.g. wash is often referred to as its washing ability, wash-ability, detergency, or wash performance. Throughout this application the term wash performance will be used to encompass this property.

#### ISOLATED DNA SEQUENCE

The term "isolated", when applied to a DNA sequence molecule, denotes that the DNA sequence has been removed from 35 its natural genetic milieu and is thus free of other extraneous or unwanted coding sequences, and is in a form suitable for use within genetically engineered protein production systems. Such isolated molecules are those that

are separated from their natural environment and include cDNA and genomic clones. Isolated DNA molecules of the present invention are free of other genes with which they are ordinarily associated, but may include naturally occurring 5' 5 and 3' untranslated regions such as promoters and terminators. The identification of associated regions will be evident to one of ordinary skill in the art (see for example, Dynan and Tijan, *Nature* 316:774-78, 1985). The term "an isolated DNA sequence" may alternatively be termed "a cloned DNA sequence".

10

#### ISOLATED PROTEIN

When applied to a protein, the term "isolated" indicates that the protein is found in a condition other than its native environment. In a preferred form, the isolated protein is 15 substantially free of other proteins, particularly other homologous proteins (i.e. "homologous impurities" (see below)). An isolated protein is more than 10 % pure, preferably more than 20 % pure, more preferably more than 30 % pure, as determined by SDS-PAGE. Further it is preferred to provide 20 the protein in a highly purified form, i.e., more than 40% pure, more than 60% pure, more than 80% pure, more preferably more than 95% pure, and even more preferably more than 99% pure, as determined by SDS-PAGE.

The term "isolated protein" may alternatively be termed 25 "purified protein".

#### HOMOLOGOUS IMPURITIES

The term "homologous impurities" means any impurity (e.g. another polypeptide than the polypeptide of the 30 invention) which originate from the homologous cell where the polypeptide of the invention is originally obtained from.

#### OBTAINED FROM

The term "obtained from" as used herein in connection 35 with a specific microbial source, means that the polynucleotide and/or polypeptide produced by the specific source, or by a cell in which a gene from the source have been inserted.

SUBSTRATE

The term "Substrate" used in connection with a substrate for a protease should be interpreted in its broadest form as comprising a compound containing at least one peptide bond susceptible to hydrolysis by a protease.

PRODUCT

The term "product" used in connection with a product derived from a protease enzymatic reaction should in the context of this invention be interpreted to include the products of a hydrolysis reaction involving a subtilase protease. A product may be the substrate in a subsequent hydrolysis reaction.

15

BRIEF DESCRIPTION OF THE DRAWING

Fig. 1 shows an alignment of 10 homologous subtilases, which are aligned to the above mentioned 18 highly conserved residues in subtilases. The 18 highly conserved residues are highlighted in bold. All shown subtilases, except JP170, have 100% identity in said conserved residues. JP170 has an asparagine "N" in position 146 in stead of the conserved glycine residue "G".

25

Fig. 2: Shows an alignment of three Savinase variants of the invention with the alignment shown in figure 1. Each of the variants 37.03, 37.04 and 37.06 is aligned individually with the alignment of Fig. 1. All three variants are shown in one figure for brevity.

Fig. 3: Shows the three-dimensional structure of Savinase (Protein data bank (PDB) entry 1 SVN). In this figure the active site loops of interest herein are indicated.

35

DETAILED DESCRIPTION OF THE INVENTIONSUBTILASE ENZYMES WITH IMPROVED WASH PERFORMANCE:

The subtilases of the invention are generally described  
5 in the preceding section "SUMMARY OF THE INVENTION"

A subtilase of the first aspect of the invention may be  
an parent wildtype subtilase identified in nature.

Such a parent wildtype subtilase may be specifically  
screened for by standard techniques known in the art.

10 One preferred way of doing this may be by specifically  
PCR amplify DNA regions known to encode active site loops in  
subtilases from numerous different microorganism, preferably  
different *Bacillus* strains.

Subtilases are a group of conserved enzymes, in the  
15 sense that their DNA and amino acid sequences are homologous.

Accordingly it is possible to construct relatively specific  
primers flanking active site loops.

E.g. by investigating alignment of different subtilases  
(see e.g. Siezen et al. Protein Science 6:501-523 (1997)), it  
20 is routine work for a person skilled in the art to construct  
PCR primers flanking e.g. the active site loop corresponding  
to active site loop between amino acid residue 95 to 103 in  
BLSAVI. Using those PCR primers to amplify DNA from a number  
of different microorganism, preferably different *Bacillus*  
25 strains, followed by DNA sequencing said amplified PCR  
fragments, it will be possible to identify those strains which  
produce subtilases, which comprises a longer, as compared to  
BLSAVI, active site region corresponding the active site  
region of 95-103 in BLSAVI. Having identified the strain and a  
30 partial DNA sequence of such a subtilase of interest, it is  
routine work for a person skilled in the art to complete  
cloning, expression and purification of such a subtilase of  
interest.

However, it is envisaged that a subtilase enzyme of the  
35 invention predominantly is a variant of a parent subtilase.

Accordingly, an embodiment of the invention relates to a  
isolated subtilase enzyme according to the first aspect of the  
invention, wherein said subtilase enzyme is a constructed

variant, wherein said variant comprises at least one insertion of at least one amino acid within at least one of the active site loops according to the first aspect of the invention.

A subtilase enzyme of the invention exhibits improved wash performance, as compared to BLSAVI (Savinase®), in a detergent. Different commercial subtilase protease products will exhibit a different wash performance in different kinds of detergent compositions. A subtilase of the invention exhibits improved wash performance, as compared to BLSAVI, in 10 a majority of different kinds of detergent compositions.

Preferably a subtilase enzyme of the invention exhibits improved wash performance, as compared to BLSAVI, in the detergent composition shown in working example 3 herein (*vide infra*).

15 In order to identify whether or not a given subtilase amino acid sequence (independent of whether said subtilase sequence is a wild type subtilase sequence isolated from nature or a subtilase variant sequence) is within the scope of a subtilase sequence of the invention, the following steps may 20 to be performed:

- i) identify if said subtilase sequence is at least 40%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 95% identical to the amino acid sequence from 25 position 1 to position 275 of subtilase BLSAVI (in BASBPN numbering);  
ii) if step i) is fulfilled, perform an alignment of said subtilase sequence to the previously defined alignment of subtilases specified in figure 1 (see 30 section "Definitions herein (*vide supra*) in order to see how this alignment preferably must be performed);  
iii) based on the alignment performed in step ii) identify the active site loops, in said subtilase 35 sequence, which correspond to the active site loop regions in BLSAVI, wherein said active site loops are specified as (in BASBPN as (in BASBPN numbering)

- (a) the region (both of the end amino acids included) between amino acid residue from 33 to 43;
- (b) the region (both of the end amino acids included) between amino acid residue 95 to 103;
- 5 (c) the region (both of the end amino acids included) between amino acid residue 125 to 132;
- (d) the region (both of the end amino acids included) between amino acid residue 153 to 173;
- (e) the region (both of the end amino acids included) 10 between amino acid residue 181 to 195;
- (f) the region (both of the end amino acids included) between amino acid residue 202 to 204; and
- (g) the region (both of the end amino acids included) between amino acid residue 218 to 219;
- 15 iv) identify whether or not one or more of the active site loops in said subtilase sequence, identified in step iii) is longer than the corresponding active site loop in BL SAVI.

20 If one the criteria in steps iv) above is fulfilled the given subtilase sequence is a subtilase sequence within the scope of the present invention.

The identity specified in step i) above between a 25 subtilase of the invention and BL SAVI is calculated as described immediately below.

IDENTITY OF AMINO ACID SEQUENCES OF A SUBTILASE OF THE INVENTION TO BL SAVI.

30 The polypeptide identity referred to above is determined as the degree of identity between the two sequences indicating a derivation of the first sequence from the second. The identity may suitably be determined by means of computer programs known in the art such as GAP provided in the GCG 35 program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman, S.B. and Wunsch, C.D., (1970), Journal of Molecular Biology, 48, 443-

453. Using GAP with the following settings for polypeptide sequence comparison: GAP creation penalty of 3.0 and GAP extension penalty of 0.1, the mature part of a subtilase amino acid sequence of the invention exhibits a degree of identity of at least 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, or even 95% with the mature part of the amino acid sequence of BLSSAVI from position 1 to position 275 (in BASBPN numbering). Accordingly, the identity will be defined as the number of identical residues divided by 269 (BLSSAVI mature part has 269 amino acids.)

The alignment to be performed in step ii) above is performed as described immediately below:

ALIGNMENT OF A SUBTILASE AMINO ACID OF THE INVENTION TO A PREVIOUSLY DEFINED ALIGNMENT OF HOMOLOGOUS SUBTILASE SEQUENCES (STEP II) ABOVE, AND IDENTIFICATION OF SUITABLE HOMOLOGOUS ACTIVE SITE LOOPS, IN SAID SUBTILASE, WHICH CORRESPOND TO THE ACTIVE SITE LOOP REGIONS IN BLSSAVI (STEP III) ABOVE).

In order to identify other homologous subtilases, within the scope of this invention, an alignment of said subtilase(s) to a group of previously aligned subtilases is performed keeping the previous alignment constant (step ii) above).

Using the CLUSTALW (version 1.7, June 1997) computer alignment program (Thompson, J.D., Higgins, D.G. and Gibson, T.J. (1994) Nucleic Acids Research, 22:4673-4680.), using default alignment parameters, alignment of a given subtilase to a group of previously aligned subtilases is achieved using the *Profile alignments* option in the program. Conservation of the, in subtilases, catalytic triad Asp32/His64/Ser221 should be maintained.

The above defined alignment of a group of subtilases is shown figure 1.

After aligning allowing for necessary insertions and deletions in order to maintain the alignment suitable homologous active site loops, in said subtilase of the invention are identified as described in step iii) above.

Based on this description it is routine for a person skilled in the art to identify suitable homologous subtilases

and corresponding homologous suitable homologous active site loops, in said subtilase.

A preferred active site loop of a subtilase of the invention as described are the loops defined as

- 5           (b) the region (both of the end amino acids included) between amino acid residue 95 to 103 is at least 10 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI); and  
10          (c) the region (both of the end amino acids included) between amino acid residue 125 to 132 is at least 9 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI).

A subtilase variant may be constructed by standard techniques known in the art such as by site-directed/random mutagenesis or by DNA shuffling of different subtilase sequences. See section "PRODUCING A SUBTILASE VARIANT" and Material and methods herein (vide infra) for further details.

- In further embodiments the invention relates to
- 20 1.an isolated subtilase enzyme according to the invention, wherein at least one of said inserted amino acid residue is chosen from the group comprising: T,G,A, and S;
- 25 2.an isolated subtilase enzyme according to the invention, wherein at least one of said inserted amino acid residue is chosen from the group of charged amino acid residues comprising: D,E,H,K, and R, more preferably D,E,K and R;
- 30 3.an isolated subtilase enzyme according to the invention, wherein at least one of said inserted amino acid residue is chosen from the group of hydrophilic amino acid residues comprising: C,N,Q,S and T, more preferably N,Q,S and T;
- 35 4.an isolated subtilase enzyme according to the invention, wherein at least one of said inserted amino acid residue is chosen from the group of small hydrophobic amino acid residues comprising: A,G and V; or
- 5.an isolated subtilase enzyme according to the invention, wherein at least one of said inserted amino acid residue is chosen from the group of large hydrophilic amino acid

residues comprising: F,I,L,M,P,W and Y, more preferably F,I,L,M, and Y.

In a further embodiment, the invention relates to an isolated subtilase enzyme according to the invention, wherein 5 said insertion, in at least one of the active site loops, comprises at least two amino acids, as compared to the corresponding active site loop in BLAVI.

In a further embodiments the invention relates to an isolated subtilase enzyme according to the invention, wherein 10 the subtilase enzyme is comprising at least one insertion, chosen from the group comprising (in BASBPN numbering) :

G97GASG;  
G97GAA; and  
G97GAS;

15 and

an isolated subtilase enzyme according to the invention, wherein the subtilase enzyme is comprising at least one insertion/modification, chosen from the group comprising (in BASBPN numbering) :

20 37.03: G97GASG + A98S+S99G+G100A+S101A;  
37.06: G97GAA + A98S+S99G+S101T; and  
37.04: G97GAS + A98S+S99G.

An alignment of residues 91 to 107 of the three latter variants is shown in Fig. 2.

25 It is well known in the art that substitution of one amino acid to a similar conservative amino acid most often only provide minor changes in the characteristic of the enzyme.

Table II below list groups of conservative amino acids.

30

Table II  
Conservative amino acid substitutions

Basic:	R = arginine
	K = lysine
	H = histidine
35 Acidic:	E = glutamic acid
	D = aspartic acid
Polar:	Q = glutamine

N = asparagine  
Hydrophobic: L = leucine  
I = isoleucine  
V = valine  
5 M = methionine  
Aromatic: F = phenylalanine  
W = tryptophan  
Y = tyrosine  
Small: G = glycine  
10 A = alanine  
S = serine  
T = threonine

Accordingly, subtilase variants such as  
15 G97GGG+A98S+S99G, are expected to exhibit a similar wash-  
performance improvement as the variant G97GAA+A98S+S99G. See  
e.g. working examples herein for a specific wash performance  
test of said G97GAA + A98S+S99G variant.

Based on the disclosed and in particular the exemplified  
20 subtilase variants herein, it is routine work, for a person  
skilled in the art, to identify further suitable conservative  
modification(s), of in particular said exemplified variants,  
in order to obtain a subtilase variant with improved wash-  
performance, according to all aspects and embodiments of the  
25 invention.

In embodiments of the invention, the subtilases of  
interest are preferably those belonging to the subgroups I-S1  
and I-S2.

Relating to subgroup I-S1 a preferred parent subtilase  
30 is chosen from the group comprising ABSS168, BASBPN, BSSDY,  
and BLSCAR or functional variants thereof having retained the  
characteristic of sub-group I-S1.

Relating to subgroup I-S2 a preferred parent subtilase  
is chosen from the group comprising BLS147, BLSAVI, BLS309,  
35 BAPB92, TVTHER AND BYSYAB or functional variants thereof  
having retained the characteristic of sub-group I-S2.

In particular said parent subtilase is BLSAVI (SAVINASE®  
NOVO NORDISK A/S) or subtilases having an identity of 95% or

more thereto, and a preferred subtilase variant of the invention is accordingly a variant of SAVINASE® or subtilases having an identity of 95% or more thereto.

The present invention also comprises any one or more 5 modifications in the above mentioned positions in combination with any other modification to the amino acid sequence of the parent enzyme. Especially combinations with other modifications known in the art to provide improved properties to the enzyme are envisaged. The art describes a number of subtilase 10 variants with different improved properties and a number of those are mentioned in the "Background of the invention" section herein (*vide supra*). Those references are disclosed here as references to identify a subtilase variant, which advantageously can be combined with a subtilase variant of the 15 invention.

Such combinations comprise the positions: 222 (improve oxidation stability), 218 (improves thermal stability), substitutions in the Ca-binding sites stabilizing the enzyme, e.g. position 76, and many other apparent from the prior art.

20 In further embodiments a subtilase variant of the invention may advantageously be combined with one or more modification(s) in any of the positions:

27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 206, 218, 222, 224, 235 and 274.

25 Specifically the following BLS309 and BAPB92 variants are considered appropriate for combination:

K27R, \*36D, S57P, N76D, S87N, G97N, S101G, S103A, V104A, V104I, V104N, V104Y, H120D, N123S, Y167, R170, Q206E, N218S, M222S, M222A, T224S, K235L and T274A.

30 Furthermore variants comprising any of the variants S101G+V104N, S87N+S101G+V104N, K27R+V104Y+N123S+T274A, N76D+S103A+V104I or N76D+V104A or other combinations of these mutations (V104N, S101G, K27R, V104Y, N123S, T274A, N76D, V104A), in combination with any one or more of the 35 modification(s) mentioned above exhibit improved properties.

Even further subtilase variants of the main aspect(s) of the invention are preferably combined with one or more modification(s) in any of the positions 129, 131, 133 and 194,

preferably as 129K, 131H, 133P, 133D and 194P modifications, and most preferably as P129K, P131H, A133P, A133D and A194P modifications. Any of those modification(s) give a higher expression level of a subtilase variant of the invention.

5 Accordingly, an even further embodiment of the invention relates to a variant according to the invention, wherein said modification is chosen from the group comprising:

Y167A+R170S+A194P  
Y167A+R170L+A194P  
10 Y167A+R170N+A194P  
Y167A+R170S+P129K  
Y167A+R170L+P129K  
Y167A+R170N+P129K  
Y167A+R170S+P131H  
15 Y167A+R170L+P131H  
Y167A+R170N+P131H  
Y167A+R170S+A133P  
Y167A+R170L+A133P  
Y167A+R170N+A133P  
20 Y167A+R170S+A133D  
Y167A+R170L+A133D  
Y167A+R170N+A133D

#### PRODUCING A SUBTILASE VARIANT

25 Many methods for cloning a subtilase of the invention and for introducing insertions into genes (e.g. subtilase genes) are well known in the art.

In general standard procedures for cloning of genes and introducing insertions (random and/or site directed) into said 30 genes may be used in order to obtain a subtilase variant of the invention. For further description of suitable techniques reference is made to working examples herein (*vide infra*) and (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; 35 Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., and

Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990); and WO 96/34946.

Further a subtilase variant of the invention may be constructed by standard techniques of DNA shuffling of 5 different subtilase genes (WO 95/22625; Stemmer WPC, Nature 370:389-91 (1994)). DNA shuffling of e.g. Savinase® with one or more partial subtilase sequences identified in nature to comprise longer than Savinase® active site loops regions, will after subsequent screening for improved wash performance 10 variants, provide subtilase variants according to the invention.

#### EXPRESSION VECTORS

A recombinant expression vector comprising a DNA 15 construct encoding the enzyme of the invention may be any vector which may conveniently be subjected to recombinant DNA procedures, and the choice of vector will often depend on the host cell into which it is to be introduced. Thus, the vector may be an autonomously replicating vector, i.e. a vector which 20 exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, e.g. a plasmid. Alternatively, the vector may be one which, when introduced into a host cell, is integrated into the host cell genome in part or in its entirety and replicated together with the 25 chromosome(s) into which it has been integrated.

The vector is preferably an expression vector in which the DNA sequence encoding the enzyme of the invention is operably linked to additional segments required for transcription of the DNA. In general, the expression vector is 30 derived from plasmid or viral DNA, or may contain elements of both. The term, "operably linked" indicates that the segments are arranged so that they function in concert for their intended purposes, e.g. transcription initiates in a promoter and proceeds through the DNA sequence coding for the enzyme.

35 The promoter may be any DNA sequence which shows transcriptional activity in the host cell of choice and may be derived from genes encoding proteins either homologous or heterologous to the host cell.

Examples of suitable promoters for use in bacterial host cells include the promoter of the *Bacillus stearothermophilus* maltogenic amylase gene, the *Bacillus licheniformis* alpha-amylase gene, the *Bacillus amyloliquefaciens* alpha-amylase gene, the *Bacillus subtilis* alkaline protease gene, or the *Bacillus pumilus* xylosidase gene, or the phage Lambda P<sub>R</sub> or P<sub>L</sub> promoters or the *E. coli* lac, trp or tac promoters.

The DNA sequence encoding the enzyme of the invention may also, if necessary, be operably connected to a suitable 10 terminator.

The recombinant vector of the invention may further comprise a DNA sequence enabling the vector to replicate in the host cell in question.

The vector may also comprise a selectable marker, e.g. a 15 gene the product of which complements a defect in the host cell, or a gene encoding resistance to e.g. antibiotics like kanamycin, chloramphenicol, erythromycin, tetracycline, spectinomycine, or the like, or resistance to heavy metals or herbicides.

20 To direct an enzyme of the present invention into the secretory pathway of the host cells, a secretory signal sequence (also known as a leader sequence, pre-pro sequence or pre sequence) may be provided in the recombinant vector. The secretory signal sequence is joined to the DNA sequence 25 encoding the enzyme in the correct reading frame. Secretory signal sequences are commonly positioned 5' to the DNA sequence encoding the enzyme. The secretory signal sequence may be that normally associated with the enzyme or may be from a gene encoding another secreted protein.

30 The procedures used to ligate the DNA sequences coding for the present enzyme, the promoter and optionally the terminator and/or secretory signal sequence, respectively, or to assemble these sequences by suitable PCR amplification schemes, and to insert them into suitable vectors containing 35 the information necessary for replication or integration, are well known to persons skilled in the art (cf., for instance, Sambrook et al., op.cit.).

HOST CELL

The DNA sequence encoding the present enzyme introduced into the host cell may be either homologous or heterologous to the host in question. If homologous to the host cell, i.e. produced by the host cell in nature, it will typically be operably connected to another promoter sequence or, if applicable, another secretory signal sequence and/or terminator sequence than in its natural environment. The term "homologous" is intended to include a DNA sequence encoding an enzyme native to the host organism in question. The term "heterologous" is intended to include a DNA sequence not expressed by the host cell in nature. Thus, the DNA sequence may be from another organism, or it may be a synthetic sequence.

The host cell into which the DNA construct or the recombinant vector of the invention is introduced may be any cell which is capable of producing the present enzyme and includes bacteria, yeast, fungi and higher eukaryotic cells.

Examples of bacterial host cells which, on cultivation, are capable of producing the enzyme of the invention are gram-positive bacteria such as strains of *Bacillus*, such as strains of *B. subtilis*, *B. licheniformis*, *B. lentus*, *B. brevis*, *B. stearothermophilus*, *B. alkalophilus*, *B. amyloliquefaciens*, *B. coagulans*, *B. circulans*, *B. laetus*, *B. megatherium* or *B. thuringiensis*, or strains of *Streptomyces*, such as *S. lividans* or *S. murinus*, or gram-negative bacteria such as *Escherichia coli*. The transformation of the bacteria may be effected by protoplast transformation, electroporation, conjugation, or by using competent cells in a manner known per se (cf. Sambrook et al., supra).

When expressing the enzyme in bacteria such as *E. coli*, the enzyme may be retained in the cytoplasm, typically as insoluble granules (known as inclusion bodies), or may be directed to the periplasmic space by a bacterial secretion sequence. In the former case, the cells are lysed and the granules are recovered and denatured after which the enzyme is

refolded by diluting the denaturing agent. In the latter case, the enzyme may be recovered from the periplasmic space by disrupting the cells, e.g. by sonication or osmotic shock, to release the contents of the periplasmic space and recovering 5 the enzyme.

When expressing the enzyme in gram-positive bacteria such as *Bacillus* or *Streptomyces* strains, the enzyme may be retained in the cytoplasm, or may be directed to the extracellular medium by a bacterial secretion sequence. In the 10 latter case, the enzyme may be recovered from the medium as described below.

#### METHOD OF PRODUCING SUBTILASE

The present invention provides a method of producing an 15 isolated enzyme according to the invention, wherein a suitable host cell, which has been transformed with a DNA sequence encoding the enzyme, is cultured under conditions permitting the production of the enzyme, and the resulting enzyme is recovered from the culture.

20 When an expression vector comprising a DNA sequence encoding the enzyme is transformed into a heterologous host cell it is possible to enable heterologous recombinant production of the enzyme of the invention.

Thereby it is possible to make a highly purified 25 subtilase composition, characterized in being free from homologous impurities.

In this context homologous impurities means any 30 impurities (e.g. other polypeptides than the enzyme of the invention) which originate from the homologous cell where the enzyme of the invention is originally obtained from.

The medium used to culture the transformed host cells may be any conventional medium suitable for growing the host cells in question. The expressed subtilase may conveniently be secreted into the culture medium and may be recovered 35 therefrom by well-known procedures including separating the cells from the medium by centrifugation or filtration, precipitating proteinaceous components of the medium by means of a salt such as ammonium sulfate, followed by chro-

matographic procedures such as ion exchange chromatography, affinity chromatography, or the like.

#### USE OF A SUBTILASE VARIANT OF THE INVENTION

5       A subtilase protease variant of the invention may be used for a number of industrial applications, in particular within the detergent industry.

Further the invention relates to an enzyme composition, which comprise a subtilase variant of the invention.

10       An summary of preferred industrial applications and corresponding preferred enzyme compositions are described below.

This summary is not in any way intended to be a complete list of suitable applications of a subtilase variant of the 15 invention. A subtilase variants of the invention may be used in other industrial applications known in the art to include use of a protease, in particular a subtilase.

#### DETERGENT COMPOSITIONS COMPRISING THE MUTANT ENZYMES

20       The present invention comprises the use of the mutant enzymes of the invention in cleaning and detergent compositions and such compositions comprising the mutant subtilisin enzymes. Such cleaning and detergent compositions are well described in the art and reference is made to WO 25 96/34946; WO 97/07202; WO 95/30011 for further description of suitable cleaning and detergent compositions.

Further reference is made to workings example(s) herein showing wash performance improvements for a number of subtilase variants of the invention.

DETERGENT DISCLOSURE AND EXAMPLESSURFACTANT SYSTEM

The detergent compositions according to the present invention comprise a surfactant system, wherein the surfactant can be selected from nonionic and/or anionic and/or cationic and/or ampholytic and/or zwitterionic and/or semi-polar surfactants.

The surfactant is typically present at a level from 0.1% to 60% by weight.

The surfactant is preferably formulated to be compatible with enzyme components present in the composition. In liquid or gel compositions the surfactant is most preferably formulated in such a way that it promotes, or at least does not degrade, the stability of any enzyme in these compositions.

Preferred systems to be used according to the present invention comprise as a surfactant one or more of the nonionic and/or anionic surfactants described herein.

Polyethylene, polypropylene, and polybutylene oxide condensates of alkyl phenols are suitable for use as the nonionic surfactant of the surfactant systems of the present invention, with the polyethylene oxide condensates being preferred. These compounds include the condensation products of alkyl phenols having an alkyl group containing from about 6 to about 14 carbon atoms, preferably from about 8 to about 14 carbon atoms, in either a straight chain or branched-chain configuration with the alkylene oxide. In a preferred embodiment, the ethylene oxide is present in an amount equal to from about 2 to about 25 moles, more preferably from about 3 to about 15 moles, of ethylene oxide per mole of alkyl phenol. Commercially available nonionic surfactants of this type include Igepal™ CO-630, marketed by the GAF Corporation; and Triton™ X-45, X-114, X-100 and X-102, all marketed by the Rohm & Haas Company. These surfactants are commonly referred to as alkylphenol alkoxylates (e.g., alkyl phenol ethoxylates).

The condensation products of primary and secondary aliphatic alcohols with about 1 to about 25 moles of ethylene oxide are suitable for use as the nonionic surfactant of the nonionic surfactant systems of the present invention. The alkyl chain of the aliphatic alcohol can either be straight or branched, primary or secondary, and generally contains from about 8 to about 22 carbon atoms. Preferred are the condensation products of alcohols having an alkyl group containing from about 8 to about 20 carbon atoms, more preferably from about 10 to about 18 carbon atoms, with from about 2 to about 10 moles of ethylene oxide per mole of alcohol. About 2 to about 7 moles of ethylene oxide and most preferably from 2 to 5 moles of ethylene oxide per mole of alcohol are present in said condensation products. Examples of commercially available nonionic surfactants of this type include Tergitol™ 15-S-9 (The condensation product of C<sub>11</sub>-C<sub>15</sub> linear alcohol with 9 moles ethylene oxide), Tergitol™ 24-L-6 NMW (the condensation product of C<sub>12</sub>-C<sub>14</sub> primary alcohol with 6 moles ethylene oxide with a narrow molecular weight distribution), both marketed by Union Carbide Corporation; Neodol™ 45-9 (the condensation product of C<sub>14</sub>-C<sub>15</sub> linear alcohol with 9 moles of ethylene oxide), Neodol™ 23-3 (the condensation product of C<sub>12</sub>-C<sub>13</sub> linear alcohol with 3.0 moles of ethylene oxide), Neodol™ 45-7 (the condensation product of C<sub>14</sub>-C<sub>15</sub> linear alcohol with 7 moles of ethylene oxide), Neodol™ 45-5 (the condensation product of C<sub>14</sub>-C<sub>15</sub> linear alcohol with 5 moles of ethylene oxide) marketed by Shell Chemical Company, Kyro™ EOB (the condensation product of C<sub>13</sub>-C<sub>15</sub> alcohol with 9 moles ethylene oxide), marketed by The Procter & Gamble Company, and Genapol LA 050 (the condensation product of C<sub>12</sub>-C<sub>14</sub> alcohol with 5 moles of ethylene oxide) marketed by Hoechst. Preferred range of HLB in these products is from 8-11 and most preferred from 8-10.

Also useful as the nonionic surfactant of the surfactant systems of the present invention are alkylpolysaccharides disclosed in US 4,565,647, having a hydrophobic group containing from about 6 to about 30 carbon atoms, preferably from about 10 to about 16 carbon atoms and a polysaccharide,

e.g. a polyglycoside, hydrophilic group containing from about 1.3 to about 10, preferably from about 1.3 to about 3, most preferably from about 1.3 to about 2.7 saccharide units. Any reducing saccharide containing 5 or 6 carbon atoms can be used, e.g., glucose, galactose and galactosyl moieties can be substituted for the glucosyl moieties (optionally the hydrophobic group is attached at the 2-, 3-, 4-, etc. positions thus giving a glucose or galactose as opposed to a glucoside or galactoside). The intersaccharide bonds can be, 10 e.g., between the one position of the additional saccharide units and the 2-, 3-, 4-, and/or 6- positions on the preceding saccharide units.

The preferred alkylpolyglycosides have the formula



wherein  $R^2$  is selected from the group consisting of alkyl, alkylphenyl, hydroxyalkyl, hydroxyalkylphenyl, and mixtures thereof in which the alkyl groups contain from about 10 to 20 about 18, preferably from about 12 to about 14, carbon atoms; n is 2 or 3, preferably 2; t is from 0 to about 10, preferably 0; and x is from about 1.3 to about 10, preferably from about 1.3 to about 3, most preferably from about 1.3 to about 2.7. The glycosyl is preferably derived from glucose. To prepare 25 these compounds, the alcohol or alkylpolyethoxy alcohol is formed first and then reacted with glucose, or a source of glucose, to form the glucoside (attachment at the 1-position). The additional glycosyl units can then be attached between their 1-position and the preceding glycosyl units 2-, 3-, 4-, 30 and/or 6-position, preferably predominantly the 2-position.

The condensation products of ethylene oxide with a hydrophobic base formed by the condensation of propylene oxide with propylene glycol are also suitable for use as the additional nonionic surfactant systems of the present 35 invention. The hydrophobic portion of these compounds will preferably have a molecular weight from about 1500 to about 1800 and will exhibit water insolubility. The addition of polyoxyethylene moieties to this hydrophobic portion tends to


increase the water solubility of the molecule as a whole, and the liquid character of the product is retained up to the point where the polyoxyethylene content is about 50% of the total weight of the condensation product, which corresponds to 5 condensation with up to about 40 moles of ethylene oxide.

Examples of compounds of this type include certain of the commercially available Pluronic™ surfactants, marketed by BASF.

Also suitable for use as the nonionic surfactant of the 10 nonionic surfactant system of the present invention, are the condensation products of ethylene oxide with the product resulting from the reaction of propylene oxide and ethylenediamine. The hydrophobic moiety of these products consists of the reaction product of ethylenediamine and excess 15 propylene oxide, and generally has a molecular weight of from about 2500 to about 3000. This hydrophobic moiety is condensed with ethylene oxide to the extent that the condensation product contains from about 40% to about 80% by weight of polyoxyethylene and has a molecular weight of from about 5,000 20 to about 11,000. Examples of this type of nonionic surfactant include certain of the commercially available Tetronic™ compounds, marketed by BASF.

Preferred for use as the nonionic surfactant of the surfactant systems of the present invention are polyethylene 25 oxide condensates of alkyl phenols, condensation products of primary and secondary aliphatic alcohols with from about 1 to about 25 moles of ethylene oxide, alkylpolysaccharides, and mixtures hereof. Most preferred are C<sub>8</sub>-C<sub>14</sub> alkyl phenol ethoxylates having from 3 to 15 ethoxy groups and C<sub>8</sub>-C<sub>18</sub> 30 alcohol ethoxylates (preferably C<sub>10</sub> avg.) having from 2 to 10 ethoxy groups, and mixtures thereof.

Highly preferred nonionic surfactants are polyhydroxy fatty acid amide surfactants of the formula




wherein R<sup>1</sup> is H, or R<sup>1</sup> is C<sub>1-4</sub> hydrocarbyl, 2-hydroxyethyl, 2-hydroxypropyl or a mixture thereof, R<sup>2</sup> is C<sub>5-31</sub> hydrocarbyl, and Z is a polyhydroxyhydrocarbyl having a linear hydrocarbyl chain with at least 3 hydroxyls directly connected to the chain, or an alkoxylated derivative thereof. Preferably, R<sup>1</sup> is methyl, R<sup>2</sup> is straight C<sub>11-15</sub> alkyl or C<sub>16-18</sub> alkyl or alkenyl chain such as coconut alkyl or mixtures thereof, and Z is derived from a reducing sugar such as glucose, fructose, maltose or lactose, in a reductive amination reaction.

Highly preferred anionic surfactants include alkyl alkoxyated sulfate surfactants. Examples hereof are water soluble salts or acids of the formula RO(A)<sub>m</sub>SO<sub>3</sub>M wherein R is an unsubstituted C<sub>10</sub>-C<sub>24</sub> alkyl or hydroxyalkyl group having a C<sub>10</sub>-C<sub>24</sub> alkyl component, preferably a C<sub>12</sub>-C<sub>20</sub> alkyl or hydroxyalkyl, more preferably C<sub>12</sub>-C<sub>18</sub> alkyl or hydroxyalkyl, A is an ethoxy or propoxy unit, m is greater than zero, typically between about 0.5 and about 6, more preferably between about 0.5 and about 3, and M is H or a cation which can be, for example, a metal cation (e.g., sodium, potassium, lithium, calcium, magnesium, etc.), ammonium or substituted-ammonium cation. Alkyl ethoxylated sulfates as well as alkyl propoxylated sulfates are contemplated herein. Specific examples of substituted ammonium cations include methyl-, dimethyl, trimethyl-ammonium cations and quaternary ammonium cations such as tetramethyl-ammonium and dimethyl piperidinium cations and those derived from alkylamines such as ethylamine, diethylamine, triethylamine, mixtures thereof, and the like. Exemplary surfactants are C<sub>12</sub>-C<sub>18</sub> alkyl polyethoxylate (1.0) sulfate (C<sub>12</sub>-C<sub>18</sub>E(1.0)M), C<sub>12</sub>-C<sub>18</sub> alkyl polyethoxylate (2.25) sulfate (C<sub>12</sub>-C<sub>18</sub>(2.25)M), and C<sub>12</sub>-C<sub>18</sub> alkyl polyethoxylate (3.0) sulfate (C<sub>12</sub>-C<sub>18</sub>E(3.0)M), and C<sub>12</sub>-C<sub>18</sub> alkyl polyethoxylate (4.0) sulfate (C<sub>12</sub>-C<sub>18</sub>E(4.0)M), wherein M is conveniently selected from sodium and potassium.

Suitable anionic surfactants to be used are alkyl ester sulfonate surfactants including linear esters of C<sub>8</sub>-C<sub>20</sub> carboxylic acids (i.e., fatty acids) which are sulfonated with gaseous SO<sub>3</sub> according to "The Journal of the American Oil Chemists Society", 52 (1975), pp. 323-329. Suitable starting

materials would include natural fatty substances as derived from tallow, palm oil, etc.

The preferred alkyl ester sulfonate surfactant, especially for laundry applications, comprise alkyl ester sulfonate surfactants of the structural formula:



wherein  $R^3$  is a  $C_8-C_{20}$  hydrocarbyl, preferably an alkyl, or combination thereof,  $R^4$  is a  $C_1-C_6$  hydrocarbyl, preferably an alkyl, or combination thereof, and M is a cation which forms a water soluble salt with the alkyl ester sulfonate. Suitable salt-forming cations include metals such as sodium, potassium, and lithium, and substituted or unsubstituted ammonium cations, such as monoethanolamine, diethanolamine, and triethanolamine. Preferably,  $R^3$  is  $C_{10}-C_{16}$  alkyl, and  $R^4$  is methyl, ethyl or isopropyl. Especially preferred are the methyl ester sulfonates wherein  $R^3$  is  $C_{10}-C_{16}$  alkyl.

Other suitable anionic surfactants include the alkyl sulfate surfactants which are water soluble salts or acids of the formula  $ROSO_3M$  wherein R preferably is a  $C_{10}-C_{24}$  hydrocarbyl, preferably an alkyl or hydroxyalkyl having a  $C_{10}-C_{20}$  alkyl component, more preferably a  $C_{12}-C_{18}$  alkyl or hydroxyalkyl, and M is H or a cation, e.g., an alkali metal cation (e.g. sodium, potassium, lithium), or ammonium or substituted ammonium (e.g. methyl-, dimethyl-, and trimethyl ammonium cations and quaternary ammonium cations such as tetramethyl-ammonium and dimethyl piperidinium cations and quaternary ammonium cations derived from alkylamines such as ethylamine, diethylamine, triethylamine, and mixtures thereof, and the like). Typically, alkyl chains of  $C_{12}-C_{16}$  are preferred for lower wash temperatures (e.g. below about 50°C) and  $C_{16}-C_{18}$  alkyl chains are preferred for higher wash temperatures (e.g. above about 50°C).

Other anionic surfactants useful for detergents purposes can also be included in the laundry detergent compositions of the present invention. These can include salts (including, for example, sodium, potassium, ammonium, and substituted ammonium salts such as mono-, di- and triethanolamine salts) of soap, C<sub>8</sub>-C<sub>22</sub> primary or secondary alkanesulfonates, C<sub>8</sub>-C<sub>24</sub> olefinsulfonates, sulfonated polycarboxylic acids prepared by sulfonation of the pyrolyzed product of alkaline earth metal citrates; e.g., as described in British patent specification No. 1,082,179, C<sub>8</sub>-C<sub>24</sub> alkylpolyglycolethersulfates (containing up to 10 moles of ethylene oxide); alkyl glycerol sulfonates, fatty acyl glycerol sulfonates, fatty oleyl glycerol sulfates, alkyl phenol ethylene oxide ether sulfates, paraffin sulfonates, alkyl phosphates, isethionates such as the acyl isethionates, N-acyl taurates, alkyl succinamates and sulfosuccinates, monoesters of sulfosuccinates (especially saturated and unsaturated C<sub>12</sub>-C<sub>18</sub> monoesters) and diesters of sulfosuccinates (especially saturated and unsaturated C<sub>6</sub>-C<sub>12</sub> diesters), acyl sarcosinates, sulfates of alkylpolysaccharides such as the sulfates of alkylpolyglucoside (the nonionic non-sulfated compounds being described below), branched primary alkyl sulfates, and alkyl polyethoxy carboxylates such as those of the formula RO(CH<sub>2</sub>CH<sub>2</sub>O)<sub>k</sub>-CH<sub>2</sub>COO-M+ wherein R is a C<sub>8</sub>-C<sub>22</sub> alkyl, k is an integer from 1 to 10, and M is a soluble salt forming cation. Resin acids and hydrogenated resin acids are also suitable, such as rosin, hydrogenated rosin, and resin acids and hydrogenated resin acids present in or derived from tall oil.

Alkylbenzene sulfonates are highly preferred. Especially preferred are linear (straight-chain) alkyl benzene sulfonates (LAS) wherein the alkyl group preferably contains from 10 to 18 carbon atoms.


Further examples are described in "Surface Active Agents and Detergents" (Vol. I and II by Schwartz, Perry and Berch). A variety of such surfactants are also generally disclosed in US 3,929,678, (Column 23, line 58 through Column 29, line 23, herein incorporated by reference).

When included therein, the laundry detergent compositions of the present invention typically comprise from about 1% to about 40%, preferably from about 3% to about 20% by weight of such anionic surfactants.

5 The laundry detergent compositions of the present invention may also contain cationic, ampholytic, zwitterionic, and semi-polar surfactants, as well as the nonionic and/or anionic surfactants other than those already described herein.

Cationic detergents suitable for use in the 10 laundry detergent compositions of the present invention are those having one long-chain hydrocarbyl group. Examples of such cationic surfactants include the ammonium surfactants such as alkyltrimethylammonium halogenides, and those surfactants having the formula:


15



wherein R<sup>2</sup> is an alkyl or alkyl benzyl group having from about 8 to about 18 carbon atoms in the alkyl chain, each R<sup>3</sup> is selected from the group consisting of -CH<sub>2</sub>CH<sub>2</sub>- , -CH<sub>2</sub>CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH(CH<sub>2</sub>OH)-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , and mixtures thereof; each R<sup>4</sup> is selected from the group consisting of C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> hydroxyalkyl, benzyl ring structures formed by joining the two R<sup>4</sup> groups, -CH<sub>2</sub>CHOHCHOHCOR<sup>6</sup>CHOHCH<sub>2</sub>OH, wherein R<sup>6</sup> is any hexose 25 or hexose polymer having a molecular weight less than about 1000, and hydrogen when y is not 0; R<sup>5</sup> is the same as R<sup>4</sup> or is an alkyl chain, wherein the total number of carbon atoms or R<sup>2</sup> plus R<sup>5</sup> is not more than about 18; each y is from 0 to about 10, and the sum of the y values is from 0 to about 15; and X is 30 any compatible anion.

Highly preferred cationic surfactants are the water soluble quaternary ammonium compounds useful in the present composition having the formula:

35



wherein R<sub>1</sub> is C<sub>8</sub>-C<sub>16</sub> alkyl, each of R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> is independently C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> hydroxy alkyl, benzyl, and -

$(C_2H_{40})_xH$  where x has a value from 2 to 5, and X is an anion. Not more than one of  $R_2$ ,  $R_3$  or  $R_4$  should be benzyl.

The preferred alkyl chain length for R<sub>1</sub> is C<sub>12</sub>-C<sub>15</sub>, particularly where the alkyl group is a mixture of chain lengths derived from coconut or palm kernel fat or is derived synthetically by olefin build up or OXO alcohols synthesis.

Preferred groups for  $R_2R_3$  and  $R_4$  are methyl and hydroxyethyl groups and the anion X may be selected from halide, methosulfate, acetate and phosphate ions.

10 Examples of suitable quaternary ammonium compounds of  
formulae (i) for use herein are:

coconut trimethyl ammonium chloride or bromide;

coconut methyl dihydroxyethyl ammonium chloride or bromide;

decyl triethyl ammonium chloride;

15 decyl dimethyl hydroxyethyl ammonium chloride or bromide;

$C_{12-15}$  dimethyl hydroxyethyl ammonium chloride or bromide;

coconut dimethyl hydroxyethyl ammonium chloride or bromide;

myristyl trimethyl ammonium methyl sulfate;

lauryl dimethyl benzyl ammonium chloride or bromide;

20 lauryl dimethyl (ethenoxy)<sub>4</sub> ammonium chloride or bromide;

choline esters (compounds of formula (i) wherein R<sub>1</sub> is

8

di-alkyl imidazolines [compounds of formula (1)].

Other cationic surfactants useful herein are also described in US 4,228,044 and in EP 000 224.

When included therein, the laundry detergent compositions of the present invention typically comprise from 0.2% to about 25%, preferably from about 1% to about 8% by weight of such cationic surfactants.

Ampholytic surfactants are also suitable for use in the laundry detergent compositions of the present invention. These surfactants can be broadly described as aliphatic derivatives of secondary or tertiary amines, or aliphatic derivatives of heterocyclic secondary and tertiary amines in which the

aliphatic radical can be straight- or branched-chain. One of the aliphatic substituents contains at least about 8 carbon atoms, typically from about 8 to about 18 carbon atoms, and at least one contains an anionic water-solubilizing group, e.g. 5 carboxy, sulfonate, sulfate. See US 3,929,678 (column 19, lines 18-35) for examples of amphotolytic surfactants.


When included therein, the laundry detergent compositions of the present invention typically comprise from 0.2% to about 15%, preferably from about 1% to about 10% by 10 weight of such amphotolytic surfactants.

Zwitterionic surfactants are also suitable for use in laundry detergent compositions. These surfactants can be broadly described as derivatives of secondary and tertiary amines, derivatives of heterocyclic secondary and tertiary 15 amines, or derivatives of quaternary ammonium, quaternary phosphonium or tertiary sulfonium compounds. See US 3,929,678 (column 19, line 38 through column 22, line 48) for examples of zwitterionic surfactants.

When included therein, the laundry detergent 20 compositions of the present invention typically comprise from 0.2% to about 15%, preferably from about 1% to about 10% by weight of such zwitterionic surfactants.

Semi-polar nonionic surfactants are a special category 25 of nonionic surfactants which include water-soluble amine oxides containing one alkyl moiety of from about 10 to about 18 carbon atoms and 2 moieties selected from the group consisting of alkyl groups and hydroxyalkyl groups containing from about 1 to about 3 carbon atoms; water-soluble phosphine oxides containing one alkyl moiety of from about 10 to about 30 18 carbon atoms and 2 moieties selected from the group consisting of alkyl groups and hydroxyalkyl groups containing from about 1 to about 3 carbon atoms; and water-soluble sulfoxides containing one alkyl moiety from about 10 to about 18 carbon atoms and a moiety selected from the group consisting of alkyl and hydroxyalkyl moieties of from about 1 to 35 about 3 carbon atoms.

Semi-polar nonionic detergent surfactants include the amine oxide surfactants having the formula:



5

wherein R<sup>3</sup> is an alkyl, hydroxyalkyl, or alkyl phenyl group or mixtures thereof containing from about 8 to about 22 carbon atoms; R<sup>4</sup> is an alkylene or hydroxyalkylene group containing from about 2 to about 3 carbon atoms or mixtures thereof; x is 10 from 0 to about 3: and each R<sup>5</sup> is an alkyl or hydroxyalkyl group containing from about 1 to about 3 carbon atoms or a polyethylene oxide group containing from about 1 to about 3 ethylene oxide groups. The R<sup>5</sup> groups can be attached to each other, e.g., through an oxygen or nitrogen atom, to form a 15 ring structure.

These amine oxide surfactants in particular include C<sub>10</sub>-C<sub>18</sub> alkyl dimethyl amine oxides and C<sub>8</sub>-C<sub>12</sub> alkoxy ethyl dihydroxy ethyl amine oxides.

When included therein, the laundry detergent 20 compositions of the present invention typically comprise from 0.2% to about 15%, preferably from about 1% to about 10% by weight of such semi-polar nonionic surfactants.

#### BUILDER SYSTEM

25 The compositions according to the present invention may further comprise a builder system. Any conventional builder system is suitable for use herein including aluminosilicate materials, silicates, polycarboxylates and fatty acids, materials such as ethylenediamine tetraacetate, metal ion 30 sequestrants such as aminopolyphosphonates, particularly ethylenediamine tetramethylene phosphonic acid and diethylene triamine pentamethylenephosphonic acid. Though less preferred for obvious environmental reasons, phosphate builders can also be used herein.

35 Suitable builders can be an inorganic ion exchange material, commonly an inorganic hydrated aluminosilicate material, more particularly a hydrated synthetic zeolite such as hydrated zeolite A, X, B, HS or MAP.

Another suitable inorganic builder material is layered silicate, e.g. SKS-6 (Hoechst). SKS-6 is a crystalline layered silicate consisting of sodium silicate ( $\text{Na}_2\text{Si}_2\text{O}_5$ ).

Suitable polycarboxylates containing one carboxy group include lactic acid, glycolic acid and ether derivatives thereof as disclosed in Belgian Patent Nos. 831,368, 821,369 and 821,370. Polycarboxylates containing two carboxy groups include the water-soluble salts of succinic acid, malonic acid, (ethylenedioxy) diacetic acid, maleic acid, diglycollic acid, tartaric acid, tartronic acid and fumaric acid, as well as the ether carboxylates described in German Offenlegungsschrift 2,446,686, and 2,446,487, US 3,935,257 and the sulfinyl carboxylates described in Belgian Patent No. 840,623. Polycarboxylates containing three carboxy groups include, in particular, water-soluble citrates, aconitrates and citraconates as well as succinate derivatives such as the carboxymethyloxysuccinates described in British Patent No. 1,379,241, lactoxysuccinates described in Netherlands Application 7205873, and the oxypolycarboxylate materials such as 2-oxa-1,1,3-propane tricarboxylates described in British Patent No. 1,387,447.

Polycarboxylates containing four carboxy groups include oxydisuccinates disclosed in British Patent No. 1,261,829, 1,1,2,2,-ethane tetracarboxylates, 1,1,3,3-propane tetracarboxylates containing sulfo substituents include the sulfosuccinate derivatives disclosed in British Patent Nos. 1,398,421 and 1,398,422 and in US 3,936,448, and the sulfonated pyrolysed citrates described in British Patent No. 1,082,179, while polycarboxylates containing phosphone substituents are disclosed in British Patent No. 1,439,000.

Alicyclic and heterocyclic polycarboxylates include cyclopentane-cis,cis-cis-tetracarboxylates, cyclopentadienide pentacarboxylates, 2,3,4,5-tetrahydro-furan - cis, cis, cis-tetracarboxylates, 2,5-tetrahydro-furan-cis, discarboxylates, 2,2,5,5,-tetrahydrofuran - tetracarboxylates, 1,2,3,4,5,6-hexane - hexacarboxylates and carboxymethyl derivatives of polyhydric alcohols such as sorbitol, mannitol and xylitol. Aromatic polycarboxylates include mellitic acid, pyromellitic

acid and the phthalic acid derivatives disclosed in British Patent No. 1,425,343.

Of the above, the preferred polycarboxylates are hydroxy-carboxylates containing up to three carboxy groups per 5 molecule, more particularly citrates.

Preferred builder systems for use in the present compositions include a mixture of a water-insoluble aluminosilicate builder such as zeolite A or of a layered silicate (SKS-6), and a water-soluble carboxylate chelating 10 agent such as citric acid.

A suitable chelant for inclusion in the detergent compositions in accordance with the invention is ethylenediamine-N,N'-disuccinic acid (EDDS) or the alkali metal, alkaline earth metal, ammonium, or substituted ammonium 15 salts thereof, or mixtures thereof. Preferred EDDS compounds are the free acid form and the sodium or magnesium salt thereof. Examples of such preferred sodium salts of EDDS include Na<sub>2</sub>EDDS and Na<sub>4</sub>EDDS. Examples of such preferred magnesium salts of EDDS include MgEDDS and Mg<sub>2</sub>EDDS. The 20 magnesium salts are the most preferred for inclusion in compositions in accordance with the invention.

Preferred builder systems include a mixture of a water-insoluble aluminosilicate builder such as zeolite A, and a water soluble carboxylate chelating agent such as citric acid.

25 Other builder materials that can form part of the builder system for use in granular compositions include inorganic materials such as alkali metal carbonates, bicarbonates, silicates, and organic materials such as the organic phosphonates, amino polyalkylene phosphonates and 30 amino polycarboxylates.

Other suitable water-soluble organic salts are the homo- or co-polymeric acids or their salts, in which the polycarboxylic acid comprises at least two carboxyl radicals separated from each other by not more than two carbon atoms.

35 Polymers of this type are disclosed in GB-A-1,596,756. Examples of such salts are polyacrylates of MW 2000-5000 and their copolymers with maleic anhydride, such copolymers having

a molecular weight of from 20,000 to 70,000, especially about 40,000.

Detergency builder salts are normally included in amounts of from 5% to 80% by weight of the composition.  
5 Preferred levels of builder for liquid detergents are from 5% to 30%.

#### ENZYMES

Preferred detergent compositions, in addition to the 10 enzyme preparation of the invention, comprise other enzyme(s) which provides cleaning performance and/or fabric care benefits.

Such enzymes include other proteases, lipases, cutinases, amylases, cellulases, peroxidases, oxidases (e.g. 15 laccases).

Proteases: Any other protease suitable for use in alkaline solutions can be used. Suitable proteases include those of animal, vegetable or microbial origin. Microbial origin is 20 preferred. Chemically or genetically modified mutants are included. The protease may be a serine protease, preferably an alkaline microbial protease or a trypsin-like protease. Examples of alkaline proteases are subtilisins, especially those derived from Bacillus, e.g., subtilisin Novo, subtilisin 25 Carlsberg, subtilisin 309, subtilisin 147 and subtilisin 168 (described in WO 89/06279). Examples of trypsin-like proteases are trypsin (e.g. of porcine or bovine origin) and the Fusarium protease described in WO 89/06270.

Preferred commercially available protease enzymes 30 include those sold under the trade names Alcalase, Savinase, Primase, Durazym, and Esperase by Novo Nordisk A/S (Denmark), those sold under the trade names Maxatase, Maxacal, Maxapem, Properase, Purafect and Purafect OXP by Genencor International, and those sold under the trade names Opticlean and 35 Optimase by Solvay Enzymes. Protease enzymes may be incorporated into the compositions in accordance with the invention at a level of from 0.00001% to 2% of enzyme protein by weight of the composition, preferably at a level of from

0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level of from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level of from 0.01% to 0.2% of enzyme protein by weight of 5 the composition.

Lipases: Any lipase suitable for use in alkaline solutions can be used. Suitable lipases include those of bacterial or fungal origin. Chemically or genetically modified mutants are 10 included.

Examples of useful lipases include a Humicola lanuginosa lipase, e.g., as described in EP 258 068 and EP 305 216, a Rhizomucor miehei lipase, e.g., as described in EP 238 023, a Candida lipase, such as a C. antarctica lipase, e.g., the C. 15 antarctica lipase A or B described in EP 214 761, a Pseudomonas lipase such as a P. alcaligenes and P. pseudoalcaligenes lipase, e.g., as described in EP 218 272, a P. cepacia lipase, e.g., as described in EP 331 376, a P. stutzeri lipase, e.g., as disclosed in GB 1,372,034, a P. 20 fluorescens lipase, a Bacillus lipase, e.g., a B. subtilis lipase (Dartois et al., (1993), Biochimica et Biophysica acta 1131, 253-260), a B. stearothermophilus lipase (JP 64/744992) and a B. pumilus lipase (WO 91/16422).

Furthermore, a number of cloned lipases may be useful, 25 including the Penicillium camembertii lipase described by Yamaguchi et al., (1991), Gene 103, 61-67), the Geotricum candidum lipase (Schimada, Y. et al., (1989), J. Biochem., 106, 383-388), and various Rhizopus lipases such as a R. delemar lipase (Hass, M.J et al., (1991), Gene 109, 117-113), 30 a R. niveus lipase (Kugimiya et al., (1992), Biosci. Biotech. Biochem. 56, 716-719) and a R. oryzae lipase.

Other types of lipolytic enzymes such as cutinases may also be useful, e.g., a cutinase derived from Pseudomonas mendocina as described in WO 88/09367, or a cutinase derived 35 from Fusarium solani pisi (e.g. described in WO 90/09446).

Especially suitable lipases are lipases such as M1 Lipase<sup>TM</sup>, Luma fast<sup>TM</sup> and Lipomax<sup>TM</sup> (Genencor), Lipolase<sup>TM</sup> and

Lipolase Ultra™ (Novo Nordisk A/S), and Lipase P "Amano" (Amano Pharmaceutical Co. Ltd.).

The lipases are normally incorporated in the detergent composition at a level of from 0.00001% to 2% of enzyme protein by weight of the composition, preferably at a level of from 0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level of from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level of from 0.01% to 0.2% of enzyme protein by weight of the composition.

Amylases: Any amylase ( $\alpha$  and/or  $\beta$ ) suitable for use in alkaline solutions can be used. Suitable amylases include those of bacterial or fungal origin. Chemically or genetically modified mutants are included. Amylases include, for example,  $\alpha$ -amylases obtained from a special strain of B. licheniformis, described in more detail in GB 1,296,839. Commercially available amylases are Duramyl™, Termamyl™, Fungamyl™ and BAN™ (available from Novo Nordisk A/S) and Rapidase™ and Maxamyl P™ (available from Genencor).

The amylases are normally incorporated in the detergent composition at a level of from 0.00001% to 2% of enzyme protein by weight of the composition, preferably at a level of from 0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level of from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level of from 0.01% to 0.2% of enzyme protein by weight of the composition.

Cellulases: Any cellulase suitable for use in alkaline solutions can be used. Suitable cellulases include those of bacterial or fungal origin. Chemically or genetically modified mutants are included. Suitable cellulases are disclosed in US 4,435,307, which discloses fungal cellulases produced from Humicola insolens. Especially suitable cellulases are the cellulases having color care benefits. Examples of such cellulases are cellulases described in European patent application No. 0 495 257.

46

Commercially available cellulases include Celluzyme™ produced by a strain of Humicola insolens, (Novo Nordisk A/S), and KAC-500(B)™ (Kao Corporation).

Cellulases are normally incorporated in the detergent composition at a level of from 0.00001% to 2% of enzyme protein by weight of the composition, preferably at a level of from 0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level of from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level of from 0.01% to 0.2% of enzyme protein by weight of the composition.

Peroxidases/Oxidases: Peroxidase enzymes are used in combination with hydrogen peroxide or a source thereof (e.g. a

percarbonate, perborate or persulfate). Oxidase enzymes are used in combination with oxygen. Both types of enzymes are used for "solution bleaching", i.e. to prevent transfer of a textile dye from a dyed fabric to another fabric when said fabrics are washed together in a wash liquor, preferably

together with an enhancing agent as described in e.g. WO 94/12621 and WO 95/01426. Suitable peroxidases/oxidases include those of plant, bacterial or fungal origin. Chemically

or genetically modified mutants are included.

Peroxidase and/or oxidase enzymes are normally incorporated in the detergent composition at a level of from 0.00001% to 2% of enzyme protein by weight of the composition, preferably at a level of from 0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level of from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level of from 0.01% to 0.2% of enzyme protein by weight of the composition.

Mixtures of the above mentioned enzymes are encompassed herein, in particular a mixture of a protease, an amylase, a lipase and/or a cellulase.

The enzyme of the invention, or any other enzyme incorporated in the detergent composition, is normally incorporated in the detergent composition at a level from 0.00001% to 2% of enzyme protein by weight of the composition.

preferably at a level from 0.0001% to 1% of enzyme protein by weight of the composition, more preferably at a level from 0.001% to 0.5% of enzyme protein by weight of the composition, even more preferably at a level from 0.01% to 0.2% of enzyme protein by weight of the composition.

BLEACHING AGENTS

Additional optional detergent ingredients that can be included in the detergent compositions of the present invention include 10 bleaching agents such as PB1, PB4 and percarbonate with a particle size of 400-800 microns. These bleaching agent components can include one or more oxygen bleaching agents and, depending upon the bleaching agent chosen, one or more bleach activators. When present oxygen bleaching compounds 15 will typically be present at levels of from about 1% to about 25%. In general, bleaching compounds are optional added components in non-liquid formulations, e.g. granular detergents.

The bleaching agent component for use herein can be any 20 of the bleaching agents useful for detergent compositions including oxygen bleaches as well as others known in the art.

The bleaching agent suitable for the present invention can be an activated or non-activated bleaching agent.

One category of oxygen bleaching agent that can be used 25 encompasses percarboxylic acid bleaching agents and salts thereof. Suitable examples of this class of agents include magnesium monoperoxyphthalate hexahydrate, the magnesium salt of meta-chloro perbenzoic acid, 4-nonylamino-4-oxoperoxybutyric acid and diperoxydodecanedioic acid. Such 30 bleaching agents are disclosed in US 4,483,781, US 740,446, EP 0 133 354 and US 4,412,934. Highly preferred bleaching agents also include 6-nonylamino-6-oxoperoxycaproic acid as described in US 4,634,551.

Another category of bleaching agents that can be used 35 encompasses the halogen bleaching agents. Examples of hypohalite bleaching agents, for example, include trichloro isocyanuric acid and the sodium and potassium dichloro isocyanurates and N-chloro and N-bromo alkane sulfonamides.

Such materials are normally added at 0.5-10% by weight of the finished product, preferably 1-5% by weight.

The hydrogen peroxide releasing agents can be used in combination with bleach activators such as tetra-  
5 acetyl ethylenediamine (TAED), nonanoyloxybenzenesulfonate (NOBS, described in US 4,412,934), 3,5-trimethylhexanoloxybenzenesulfonate (ISONOBS, described in EP 120 591) or pentaacetylglucose (PAG), which are perhydrolyzed to form a peracid as the active bleaching species, leading to improved  
10 bleaching effect. In addition, very suitable are the bleach activators C8 (6-octanamido-caproyl) oxybenzene-sulfonate, C9 (6-nonenamido caproyl) oxybenzenesulfonate and C10 (6-decanamido caproyl) oxybenzenesulfonate or mixtures thereof.  
Also suitable activators are acylated citrate esters such as  
15 disclosed in European Patent Application No. 91870207.7.

Useful bleaching agents, including peroxyacids and bleaching systems comprising bleach activators and peroxygen bleaching compounds for use in cleaning compositions according to the invention are described in application USSN 08/136,626.

20 The hydrogen peroxide may also be present by adding an enzymatic system (i.e. an enzyme and a substrate therefore) which is capable of generation of hydrogen peroxide at the beginning or during the washing and/or rinsing process. Such enzymatic systems are disclosed in European Patent Application  
25 EP 0 537 381.

Bleaching agents other than oxygen bleaching agents are also known in the art and can be utilized herein. One type of non-oxygen bleaching agent of particular interest includes photoactivated bleaching agents such as the sulfonated zinc  
30 and/or aluminum phthalocyanines. These materials can be deposited upon the substrate during the washing process. Upon irradiation with light, in the presence of oxygen, such as by hanging clothes out to dry in the daylight, the sulfonated zinc phthalocyanine is activated and, consequently, the  
35 substrate is bleached. Preferred zinc phthalocyanine and a photoactivated bleaching process are described in US 4,033,718. Typically, detergent composition will contain about

0.025% to about 1.25%, by weight, of sulfonated zinc phthalocyanine.

Bleaching agents may also comprise a manganese catalyst. The manganese catalyst may, e.g., be one of the compounds described in "Efficient manganese catalysts for low-temperature bleaching", Nature 369, 1994, pp. 637-639.

#### SUDS SUPPRESSORS

Another optional ingredient is a suds suppressor, exemplified by silicones, and silica-silicone mixtures. Silicones can generally be represented by alkylated polysiloxane materials, while silica is normally used in finely divided forms exemplified by silica aerogels and xerogels and hydrophobic silicas of various types. These materials can be incorporated as particulates, in which the suds suppressor is advantageously releasably incorporated in a water-soluble or water-dispersible, substantially non surface-active detergent impermeable carrier. Alternatively the suds suppressor can be dissolved or dispersed in a liquid carrier and applied by spraying on to one or more of the other components.

A preferred silicone suds controlling agent is disclosed in US 3,933,672. Other particularly useful suds suppressors are the self-emulsifying silicone suds suppressors, described in German Patent Application DTOS 2,646,126. An example of such a compound is DC-544, commercially available from Dow Corning, which is a siloxane-glycol copolymer. Especially preferred suds controlling agent are the suds suppressor system comprising a mixture of silicone oils and 2-alkyl-alkanols. Suitable 2-alkyl-alkanols are 2-butyl-octanol which are commercially available under the trade name Isofol 12 R.

Such suds suppressor system are described in European Patent Application EP 0 593 841.

Especially preferred silicone suds controlling agents are described in European Patent Application No. 92201649.8. Said compositions can comprise a silicone/ silica mixture in combination with fumed nonporous silica such as Aerosil®.

The suds suppressors described above are normally employed at levels of from 0.001% to 2% by weight of the composition, preferably from 0.01% to 1% by weight.

5 OTHER COMPONENTS

Other components used in detergent compositions may be employed such as soil-suspending agents, soil-releasing agents, optical brighteners, abrasives, bactericides, tarnish inhibitors, coloring agents, and/or encapsulated or 10 nonencapsulated perfumes.

Especially suitable encapsulating materials are water soluble capsules which consist of a matrix of polysaccharide and polyhydroxy compounds such as described in GB 1,464,616.

Other suitable water soluble encapsulating materials 15 comprise dextrins derived from ungelatinized starch acid esters of substituted dicarboxylic acids such as described in US 3,455,838. These acid-ester dextrins are, preferably, prepared from such starches as waxy maize, waxy sorghum, sago, tapioca and potato. Suitable examples of said encapsulation 20 materials include N-Lok manufactured by National Starch. The N-Lok encapsulating material consists of a modified maize starch and glucose. The starch is modified by adding mono-functional substituted groups such as octenyl succinic acid anhydride.


25 Antiredeposition and soil suspension agents suitable herein include cellulose derivatives such as methylcellulose, carboxymethylcellulose and hydroxyethylcellulose, and homo- or co-polymeric polycarboxylic acids or their salts. Polymers of this type include the polyacrylates and maleic anhydride- 30 acrylic acid copolymers previously mentioned as builders, as well as copolymers of maleic anhydride with ethylene, methylvinyl ether or methacrylic acid, the maleic anhydride constituting at least 20 mole percent of the copolymer. These materials are normally used at levels of from 0.5% to 10% by 35 weight, more preferably from 0.75% to 8%, most preferably from 1% to 6% by weight of the composition.

Preferred optical brighteners are anionic in character, examples of which are disodium 4,4'-bis-(2-diethanolamino-4-

anilino -s- triazin-6-ylamino)stilbene-2:2' disulfonate,  
disodium 4, - 4'-bis-(2-morpholino-4-anilino-s-triazin-6-  
ylamino-stilbene-2:2' - disulfonate, disodium 4,4' - bis-(2,4'-  
dianilino-s-triazin-6-ylamino)stilbene-2:2' - disulfonate,  
5 monosodium 4',4'' - bis-(2,4-dianilino-s-tri-azin-6  
ylamino)stilbene-2-sulphonate, disodium 4,4' -bis-(2-anilino-  
4-(N-methyl-N-2-hydroxyethylamino)-s-triazin-6-  
ylamino)stilbene-2,2' - disulfonate, di-sodium 4,4' -bis-(4-  
phenyl-2,1,3-triazol-2-yl)-stilbene-2,2' disulfonate, di-so-  
10 dium 4,4'bis(2-anilino-4-(1-methyl-2-hydroxyethylamino)-s-  
triazin-6-ylami-no)stilbene-2,2'disulphonate, sodium  
2(stilbyl-4'''-(naphtho-1',2':4,5)-1,2,3, - triazole-2'''-  
sulphonate and 4,4'-bis(2-sulphostyryl)biphenyl.

Other useful polymeric materials are the polyethylene  
15 glycols, particularly those of molecular weight 1000-10000,  
more particularly 2000 to 8000 and most preferably about 4000.  
These are used at levels of from 0.20% to 5% more preferably  
from 0.25% to 2.5% by weight. These polymers and the  
previously mentioned homo- or co-polymeric poly-carboxylate  
20 salts are valuable for improving whiteness maintenance, fabric  
ash deposition, and cleaning performance on clay,  
proteinaceous and oxidizable soils in the presence of  
transition metal impurities.

Soil release agents useful in compositions of the  
25 present invention are conventionally copolymers or terpolymers  
of terephthalic acid with ethylene glycol and/or propylene  
glycol units in various arrangements. Examples of such  
polymers are disclosed in US 4,116,885 and 4,711,730 and EP 0  
272 033. A particular preferred polymer in accordance with EP  
30 0 272 033 has the formula:



where PEG is  $-(OC_2H_4)_n-$ , PO is  $(OC_3H_6O)$  and T is  $(pOOC_6H_4CO)$ .

35

Also very useful are modified polyesters as random  
copolymers of dimethyl terephthalate, dimethyl  
sulfoisophthalate, ethylene glycol and 1,2-propanediol, the

end groups consisting primarily of sulfobenzoate and secondarily of mono esters of ethylene glycol and/or 1,2-propanediol. The target is to obtain a polymer capped at both end by sulfobenzoate groups, "primarily", in the present context most of said copolymers herein will be end-capped by sulfobenzoate groups. However, some copolymers will be less than fully capped, and therefore their end groups may consist of monoesters of ethylene glycol and/or 1,2-propanediol, thereof consist "secondarily" of such species.

The selected polyesters herein contain about 46% by weight of dimethyl terephthalic acid, about 16% by weight of 1,2-propanediol, about 10% by weight ethylene glycol, about 13% by weight of dimethyl sulfobenzoic acid and about 15% by weight of sulfoisophthalic acid, and have a molecular weight of about 3.000. The polyesters and their method of preparation are described in detail in EP 311 342.

Softening agents: Fabric softening agents can also be incorporated into laundry detergent compositions in accordance with the present invention. These agents may be inorganic or organic in type. Inorganic softening agents are exemplified by the smectite clays disclosed in GB-A-1 400898 and in US 5,019,292. Organic fabric softening agents include the water insoluble tertiary amines as disclosed in GB-A1 514 276 and EP 0 011 340 and their combination with mono C<sub>12</sub>-C<sub>14</sub> quaternary ammonium salts are disclosed in EP-B-0 026 528 and di-long-chain amides as disclosed in EP 0 242 919. Other useful organic ingredients of fabric softening systems include high molecular weight polyethylene oxide materials as disclosed in EP 0 299 575 and 0 313 146.

Levels of smectite clay are normally in the range from 5% to 15%, more preferably from 8% to 12% by weight, with the material being added as a dry mixed component to the remainder of the formulation. Organic fabric softening agents such as the water-insoluble tertiary amines or di-long chain amide materials are incorporated at levels of from 0.5% to 5% by weight, normally from 1% to 3% by weight whilst the high molecular weight polyethylene oxide materials and the water

soluble cationic materials are added at levels of from 0.1% to 2%, normally from 0.15% to 1.5% by weight. These materials are normally added to the spray dried portion of the composition; although in some instances it may be more convenient to add them as a dry mixed particulate, or spray them as molten liquid on to other solid components of the composition.

Polymeric dye-transfer inhibiting agents: The detergent compositions according to the present invention may also 10 comprise from 0.001% to 10%, preferably from 0.01% to 2%, more preferably from 0.05% to 1% by weight of polymeric dye-transfer inhibiting agents. Said polymeric dye-transfer inhibiting agents are normally incorporated into detergent compositions in order to inhibit the transfer of dyes from 15 colored fabrics onto fabrics washed therewith. These polymers have the ability of complexing or adsorbing the fugitive dyes washed out of dyed fabrics before the dyes have the opportunity to become attached to other articles in the wash.

Especially suitable polymeric dye-transfer inhibiting 20 agents are polyamine N-oxide polymers, copolymers of N-vinyl-pyrrolidone and N-vinylimidazole, polyvinylpyrrolidone polymers, polyvinyloxazolidones and polyvinylimidazoles or mixtures thereof.

Addition of such polymers also enhances the performance 25 of the enzymes according the invention.

The detergent composition according to the invention can be in liquid, paste, gels, bars or granular forms.

Non-dusting granulates may be produced, e.g., as disclosed in US 4,106,991 and 4,661,452 (both to Novo Industri 30 A/S) and may optionally be coated by methods known in the art. Examples of waxy coating materials are poly(ethylene oxide) products (polyethyleneglycol, PEG) with mean molecular weights of 1000 to 20000; ethoxylated nonylphenols having from 16 to 50 ethylene oxide units; ethoxylated fatty alcohols in which 35 the alcohol contains from 12 to 20 carbon atoms and in which there are 15 to 80 ethylene oxide units; fatty alcohols; fatty acids; and mono- and di- and triglycerides of fatty acids.

Examples of film-forming coating materials suitable for application by fluid bed techniques are given in GB 1483591.

Granular compositions according to the present invention can also be in "compact form", i.e. they may have a relatively higher density than conventional granular detergents, i.e. 5 form 550 to 950 g/l; in such case, the granular detergent compositions according to the present invention will contain a lower amount of "Inorganic filler salt", compared to conventional granular detergents; typical filler salts are 10 alkaline earth metal salts of sulfates and chlorides, typically sodium sulfate; "Compact" detergent typically comprise not more than 10% filler salt. The liquid compositions according to the present invention can also be in "concentrated form", in such case, the liquid detergent 15 compositions according to the present invention will contain a lower amount of water, compared to conventional liquid detergents. Typically, the water content of the concentrated liquid detergent is less than 30%, more preferably less than 20%, most preferably less than 10% by weight of the detergent 20 compositions.

The compositions of the invention may for example, be formulated as hand and machine laundry detergent compositions including laundry additive compositions and compositions suitable for use in the pretreatment of stained fabrics, rinse 25 added fabric softener compositions, and compositions for use in general household hard surface cleaning operations and dishwashing operations.

The following examples are meant to exemplify compositions for the present invention, but are not 30 necessarily meant to limit or otherwise define the scope of the invention.

In the detergent compositions, the abbreviated component identifications have the following meanings:

35 LAS: Sodium linear C<sub>12</sub> alkyl benzene sulfonate

TAS: Sodium tallow alkyl sulfate

XYAS: Sodium C<sub>1x</sub> - C<sub>1y</sub> alkyl sulfate

SS: Secondary soap surfactant of formula 2-butyl octanoic acid

25EY: A C<sub>12</sub> - C<sub>15</sub> predominantly linear primary alcohol condensed with an average of Y moles of ethylene oxide

5 45EY: A C<sub>14</sub> - C<sub>15</sub> predominantly linear primary alcohol condensed with an average of Y moles of ethylene oxide

10 XYEZS: C<sub>1x</sub> - C<sub>1y</sub> sodium alkyl sulfate condensed with an average of Z moles of ethylene oxide per mole

Nonionic: C<sub>13</sub> - C<sub>15</sub> mixed ethoxylated/propoxylated fatty alcohol with an average degree of ethoxylation of 3.8 and an average degree of propoxylation of 4.5

15 sold under the trade name Plurafax LF404 by BASF GmbH

CFAA: C<sub>12</sub> - C<sub>14</sub> alkyl N-methyl glucamide

TFAA: C<sub>16</sub> - C<sub>18</sub> alkyl N-methyl glucamide

Silicate: Amorphous Sodium Silicate (SiO<sub>2</sub>:Na<sub>2</sub>O ratio = 2.0)

20 NaSKS-6: Crystalline layered silicate of formula δ-Na<sub>2</sub>Si<sub>2</sub>O<sub>5</sub>

Carbonate: Anhydrous sodium carbonate

Phosphate: Sodium tripolyphosphate

MA/AA: Copolymer of 1:4 maleic/acrylic acid, average molecular weight about 80,000

25 Poly-

acrylate: Polyacrylate homopolymer with an average molecular weight of 8,000 sold under the trade name PA30 by BASF GmbH

Zeolite A: Hydrated Sodium Aluminosilicate of formula Na<sub>12</sub>(AlO<sub>2</sub>SiO<sub>2</sub>)<sub>12</sub>.27H<sub>2</sub>O having a primary particle size in the range from 1 to 10 micrometers

30 Citrate: Tri-sodium citrate dihydrate

Citric: Citric Acid

Perborate: Anhydrous sodium perborate mono-hydrate bleach, empirical formula NaBO<sub>2</sub>.H<sub>2</sub>O<sub>2</sub>

35 PB4: Anhydrous sodium perborate tetra-hydrate

Percar-

bonate: Anhydrous sodium percarbonate bleach of empirical formula 2Na<sub>2</sub>CO<sub>3</sub>.3H<sub>2</sub>O<sub>2</sub>

TAED: Tetraacetyl ethylene diamine

CMC: Sodium carboxymethyl cellulose

5 DETPMP: Diethylene triamine penta (methylene phosphonic acid), marketed by Monsanto under the Trade name Dequest 2060

PVP: Polyvinylpyrrolidone polymer

EDDS: Ethylenediamine-N, N'-disuccinic acid, [S,S] isomer in the form of the sodium salt

10 Suds 25% paraffin wax Mpt 50°C, 17% hydrophobic silica, 58%

Suppressor: paraffin oil

Granular

15 Suds: 12% Silicone/silica, 18% stearyl alcohol, 70% Suppressor: starch in granular form

Sulfate: Anhydrous sodium sulfate

HMWPEO: High molecular weight polyethylene oxide

TAE 25: Tallow alcohol ethoxylate (25)

20

DETERGENT EXAMPLE I

A granular fabric cleaning composition in accordance with the invention may be prepared as follows:

25	Sodium linear C <sub>12</sub> alkyl benzene sulfonate	6.5
	Sodium sulfate	15.0
	Zeolite A	26.0
	Sodium nitrilotriacetate	5.0
30	Enzyme of the invention	0.1
	PVP	0.5
	TAED	3.0
	Boric acid	4.0
	Perborate	18.0
35	Phenol sulfonate	0.1
	Minors	Up to 100

DETERGENT EXAMPLE II

A compact granular fabric cleaning composition (density 800 g/l) in accord with the invention may be prepared as follows:

5	45AS	8.0
	25E3S	2.0
	25E5	3.0
	25E3	3.0
	TFAA	2.5
10	Zeolite A	17.0
	NaSKS-6	12.0
	Citric acid	3.0
	Carbonate	7.0
	MA/AA	5.0
15	CMC	0.4
	Enzyme of the invention	0.1
	TAED	6.0
	Percarbonate	22.0
	EDDS	0.3
20	Granular suds suppressor	3.5
	water/minors	Up to 100%

#### DETERGENT EXAMPLE III

Granular fabric cleaning compositions in accordance with 25 the invention which are especially useful in the laundering of colored fabrics were prepared as follows:

	LAS	10.7	-
	TAS	2.4	-
	TFAA	-	4.0
30	45AS	3.1	10.0
	45E7	4.0	-
	25E3S	-	3.0
	68E11	1.8	-
	25E5	-	8.0
35	Citrate	15.0	7.0
	Carbonate	-	10
	Citric acid	2.5	3.0
	Zeolite A	32.1	25.0

	Na-SKS-6	-	9.0
	MA/AA	5.0	5.0
	DETPMP	0.2	0.8
	Enzyme of the invention	0.10	0.05
5	Silicate	2.5	-
	Sulfate	5.2	3.0
	PVP	0.5	-
	Poly (4-vinylpyridine)-N-Oxide/copolymer of vinyl-imidazole and vinyl-pyrrolidone	-	0.2
10	Perborate	1.0	-
	Phenol sulfonate	0.2	-
	Water/Minors	Up to 100%	

15

DETERGENT EXAMPLE IV

Granular fabric cleaning compositions in accordance with the invention which provide "Softening through the wash" capability may be prepared as follows:

20	45AS	-	10.0
	LAS	7.6	-
	68AS	1.3	-
	45E7	4.0	-
	25E3	-	5.0
25	Coco-alkyl-dimethyl hydroxy-ethyl ammonium chloride	1.4	1.0
	Citrate	5.0	3.0
	Na-SKS-6	-	11.0
	Zeolite A	15.0	15.0
30	MA/AA	4.0	4.0
	DETPMP	0.4	0.4
	Perborate	15.0	-
	Percarbonate	-	15.0
	TAED	5.0	5.0
35	Smectite clay	10.0	10.0
	HMWPEO	-	0.1
	Enzyme of the invention	0.10	0.05
	Silicate	3.0	5.0
	Carbonate	10.0	10.0
40	Granular suds suppressor	1.0	4.0

CMC	0.2	0.1
Water/Minors	Up to 100%	

DETERGENT EXAMPLE V

5 Heavy duty liquid fabric cleaning compositions in accordance with the invention may be prepared as follows:

	I	II
LAS acid form	-	25.0
10 Citric acid	5.0	2.0
25AS acid form	8.0	-
25AE2S acid form	3.0	-
25AE7	8.0	-
CFAA	5	-
15 DETPMP	1.0	1.0
Fatty acid	8	-
Oleic acid	-	1.0
Ethanol	4.0	6.0
Propanediol	2.0	6.0
20 Enzyme of the invention	0.10	0.05
Coco-alkyl dimethyl hydroxy ethyl ammonium chloride	-	3.0
Smectite clay	-	5.0
25 PVP	2.0	-
Water / Minors	Up to 100%	

LEATHER INDUSTRY APPLICATIONS

A subtilase of the invention may be used in the leather industry, in particular for use in depilation of skins.

In said application a subtilase variant of the invention is preferably used in an enzyme composition which further comprise another protease.

For a more detailed description of suitable other proteases see section relating to suitable enzymes for use in a detergent composition (*vide supra*).

WOOL INDUSTRY APPLICATIONS

A subtilase of the invention may be used in the wool industry, in particular for use in cleaning of clothes comprising wool.

In said application a subtilase variant of the invention 5 is preferably used in an enzyme composition which further comprise another protease.

For a more detailed description of suitable other proteases see section relating to suitable enzymes for use in a detergent composition (*vide supra*).

10 The invention is described in further detail in the following examples which are not in any way intended to limit the scope of the invention as claimed.

#### MATERIALS AND METHODS

15

##### STRAINS:

*B. subtilis* DN1885 (Diderichsen et al., 1990).

16 *B. latus* 309 and 147 are specific strains of *Bacillus latus*, deposited with the NCIB and accorded the accession numbers NCIB 10309 and 10147, and described in US Patent No. 3,723,250 incorporated by reference herein.

20 *E. coli* MC 1000 (M.J. Casadaban and S.N. Cohen (1980); *J. Mol. Biol.* 138 179-207), was made *r*<sup>-</sup>,*m*<sup>+</sup> by conventional methods and is also described in US Patent Application Serial 25 No. 039,298.

##### PLASMIDS:

26 pJS3: *E. coli* - *B. subtilis* shuttle vector containing a synthetic gene encoding for subtilase 309. (Described by Jacob Schiødt et al. in *Protein and Peptide letters* 3:39-44 (1996)).

PSX222: *B. subtilis* expression vector (Described in WO 96/34946).

##### GENERAL MOLECULAR BIOLOGY METHODS:

31 Unless otherwise mentioned the DNA manipulations and transformations were performed using standard methods of

molecular biology (Sambrook et al. (1989) Molecular cloning: A laboratory manual, Cold Spring Harbor lab., Cold Spring Harbor, NY; Ausubel, F. M. et al. (eds.) "Current protocols in Molecular Biology". John Wiley and Sons, 1995; Harwood, C. R., 5 and Cutting, S. M. (eds.) "Molecular Biological Methods for Bacillus". John Wiley and Sons, 1990).

Enzymes for DNA manipulations were used according to the specifications of the suppliers.

10 ENZYMES FOR DNA MANIPULATIONS

Unless otherwise mentioned all enzymes for DNA manipulations, such as e.g. restriction endonucleases, ligases etc., are obtained from New England Bolas, Inc.

15 PROTEOLYTIC ACTIVITY

In the context of this invention proteolytic activity is expressed in Kilo NOVO Protease Units (KNPU). The activity is determined relatively to an enzyme standard (SAVINASE<sup>®</sup>), and the determination is based on the digestion of a dimethyl 20 casein (DMC) solution by the proteolytic enzyme at standard conditions, i.e. 50°C, pH 8.3, 9 min. reaction time, 3 min. measuring time. A folder AF 220/1 is available upon request to Novo Nordisk A/S, Denmark, which folder is hereby included by reference.

25 A GU is a Glycine Unit, defined as the proteolytic enzyme activity which, under standard conditions, during a 15 minutes' incubation at 40°C, with N-acetyl casein as substrate, produces an amount of NH<sub>2</sub>-group equivalent to 1 mmole of glycine.

30 Enzyme activity can also be measured using the PNA assay, according to reaction with the soluble substrate succinyl-alanine-alanine-proline-phenyl-alanine-para-nitrophenol, which is described in the Journal of American Oil Chemists Society, Rothgeb, T.M., Goodlander, B.D., Garrison, 35 P.H., and Smith, L.A., (1988).

FERMENTATION:

Fermentation of subtilase enzymes were performed at 30°C on a rotary shaking table (300 r.p.m.) in 500 ml baffled Erlenmeyer flasks containing 100 ml BPX medium for 5 days.

5 Consequently in order to produce e.g. 2 liter broth, 20 Erlenmeyer flasks were fermented simultaneously.

MEDIA:BPX: Composition (per liter)

10	Potato starch	100g
	Ground barley	50g
	Soybean flour	20g
	Na <sub>2</sub> HPO <sub>4</sub> X 12 H <sub>2</sub> O	9g
	Pluronic	0.1g
15	Sodium caseinate	10g

The starch in the medium is liquefied with α-amylase and the medium is sterilized by heating at 120°C for 45 minutes. After sterilization the pH of the medium is adjusted to 9 by 20 addition of NaHCO<sub>3</sub> to 0.1 M.

**EXAMPLE 1**CONSTRUCTION AND EXPRESSION OF ENZYME VARIANTS

## 25 SITE-DIRECTED MUTAGENESIS:

Subtilase 309 site-directed variants, where specific insertions were performed in one the active site loops according to the invention, was made by the "Unique site elimination (USE)" or the "Uracil-USE" technique described 30 respectively by Deng et al. (Anal. Biochem. 200:81-88 (1992)) and Markvardsen et al. (BioTechniques 18(3):371-372 (1995)).

The template plasmid was pJS3, or an analogue of this containing a variant of Subtilase 309, e.g. USE mutagenesis was performed with an oligonucleotide directed to the 35 construction of a G97GASG insertion variant resulting in a final G97GASG Subtilase 309 variant.

The Subtilase 309 variants constructed in pJS3 were then subcloned into the *B. subtilis* pSX222 expression plasmid, using the restriction enzymes KpnI and MluI.

5 LOCALIZED RANDOM MUTAGENESIS IN ORDER TO INSERT RANDOM  
INSERTIONS IN A LOCALIZED REGION:

The overall strategy used to perform localized random mutagenesis was:

a mutagenic primer (oligonucleotide) was synthesized  
10 which corresponds to the part of the DNA sequence to be modified except for the nucleotide(s) corresponding to amino acid codon(s) to be modified by insertions.

Subsequently, the resulting mutagenic primer was used in a PCR reaction with a suitable opposite primer. The resulting  
15 PCR fragment was purified and digested and cloned into a *E. coli*-*B. subtilis* shuttle vector.

Alternatively, and if necessary, the resulting PCR fragment is used in a second PCR reaction as a primer with a second suitable opposite primer so as to allow digestion and  
20 cloning of the mutagenized region into the shuttle vector. The PCR reactions are performed under normal conditions.

Following this strategy a localized random library was constructed in SAVINASE wherein insertions were introduced in the active site loop region from 95-103.

25 The mutations/insertions were introduced by mutagenic primers (see below), so that only four amino acids: Thr, Gly, Ala and Ser are represented with two codons each (R = 50% A and G; S = 50% C and G; and Y = 50% C and T). The produced PCR fragment were cloned into the Avr II and Not I sites of  
30 plasmid pJS3, and ten randomly chosen *E. coli* colonies were sequenced to confirm the mutations designed.

The mutagenic primer (5'- CTA TAC GCT AAA GTC CTA GGG GCG RSY RSY RSY RSY RSY RSY GTC AGC TCG ATT GCC CAA GG -3' (sense)) were used in a PCR reaction with a suitable anti-sense opposite primer, situated downstream of the MluI site in  
35 pJS3 (e.g. 5'- CCC TTT AAC CGC ACA GCG TTT -3' (anti-sense)) and the plasmid pJS3 as template. This resulting PCR product

was cloned into the pJS3 shuttle vector by using the restriction enzymes Avr II and Not I.

The localized random library constructed in pJS3 was then subcloned into the *B. subtilis* pSX222 expression plasmid, 5 using the restriction enzymes KpnI and MluI.

The library prepared contained approximately 100,000 individual clones/library.

Ten randomly chosen colonies were sequenced to confirm the mutations designed.

10 In order to purify a subtilase variant of the invention the *B. subtilis* pSX222 expression plasmid comprising a variant of the invention was transformed into a competent *B. subtilis* strain and was fermented as described above in a medium containing 10 µg/ml Chloramphenicol (CAM).

15

#### EXAMPLE 2

##### PURIFICATION OF ENZYME VARIANTS

This procedure describes the purification of a 2 litre 20 scale fermentation of the Subtilisin 147 enzyme, the Subtilisin 309 enzyme or mutants thereof.

Approximately 1.6 litres of fermentation broth were centrifuged at 5000 rpm for 35 minutes in 1 litre beakers. The supernatants were adjusted to pH 6.5 using 10% acetic acid and 25 filtered on Seitz Supra S100 filter plates.

The filtrates were concentrated to approximately 400 ml using an Amicon CH2A UF unit equipped with an Amicon S1Y10 UF cartridge. The UF concentrate was centrifuged and filtered prior to absorption at room temperature on a Bacitracin affinity column at pH 7. The protease was eluted from the Bacitracin column at room temperature using 25% 2-propanol and 1 M sodium chloride in a buffer solution with 0.01 dimethyl-glutaric acid, 0.1 M boric acid and 0.002 M calcium chloride adjusted to pH 7.

35 The fractions with protease activity from the Bacitracin purification step were combined and applied to a 750 ml Sephadex G25 column (5 cm dia.) equilibrated with a buffer

containing 0.01 dimethylglutaric acid, 0.2 M boric acid and 0.002 M calcium chloride adjusted to pH 6.5.

Fractions with proteolytic activity from the Sephadex G25 column were combined and applied to a 150 ml CM Sepharose 5 CL 6B cation exchange column (5 cm dia.) equilibrated with a buffer containing 0.01 M dimethylglutaric acid, 0.2 M boric acid, and 0.002 M calcium chloride adjusted to pH 6.5.

The protease was eluted using a linear gradient of 0-0.1 M sodium chloride in 2 litres of the same buffer (0-0.2 M sodium chloride in case of Subtilisin 147).

In a final purification step protease containing fractions from the CM Sepharose column were combined and concentrated in an Amicon ultrafiltration cell equipped with a GR81PP membrane (from the Danish Sugar Factories Inc.).

By using the techniques of Example 1 for the construction and the above isolation procedure the following subtilisin 309 variants were produced and isolated:

37.03: G97GASG + A98S+S99G+G100A+S101A;

37.06: G97GAA + A98S+S99G+S101T; and

37.04: G97GAS + A98S+S99G.

### EXAMPLE 3

#### WASH PERFORMANCE OF DETERGENT COMPOSITIONS COMPRISING ENZYME

##### 25 VARIANTS

The following example provides results from a number of washing tests that were conducted under the conditions indicated

##### 30 EXPERIMENTAL CONDITIONS

Table III: Experimental conditions for evaluation of Subtilisin 309 variants.

Detergent	Protease Model Detergent 95
Detergent dose	3.0 g/l
pH	10.5
Wash time	15 min.

Temperature	15 °C
Water hardness	6 °dH
Enzymes	Subtilisin 309 variants as listed below
Enzyme conc.	10 nM
Test system	150 ml glass beakers with a stirring rod
Textile/volume	5 textile pieces ( $\varnothing$ 2.5 cm) in 50 ml detergent
Test material	EMPA117 from Center for Testmaterials, Holland

The detergent used is a simple model formulation. pH is adjusted to 10.5 which is within the normal range for a powder detergent. The composition of model detergent 95 is as follows:

STP (Na <sub>5</sub> P <sub>3</sub> O <sub>10</sub> )	25%
Na <sub>2</sub> SO <sub>4</sub>	25%
Na <sub>2</sub> CO <sub>3</sub>	10%
10 LAS (Nansa 80S)	20%
Nonionic tenside (Dobanol 25-7)	5.0%
Na <sub>2</sub> Si <sub>2</sub> O <sub>5</sub>	5.0%
Carboxymethylcellulose (CMC)	0.5%
Water	9.5%

15

Water hardness was adjusted by adding CaCl<sub>2</sub> and MgCl<sub>2</sub> (Ca<sup>2+</sup>:Mg<sup>2+</sup> = 2:1) to deionized water (see also Surfactants in Consumer Products - Theory, Technology and Application, Springer Verlag 1986). pH of the detergent solution was 20 adjusted to pH 10.5 by addition of HCl.

Measurement of reflectance (R) on the test material was done at 460 nm using a Macbeth ColorEye 7000 photometer. The measurements were done according to the manufacturers protocol.

The wash performance of the Subtilisin 309 variants was evaluated by calculating a performance factor:

$$P = \frac{R_{\text{Variant}} - R_{\text{Blank}}}{R_{\text{Savinase}} - R_{\text{Blank}}}$$

5

P: Performance factor

$R_{\text{Variant}}$ : Reflectance of test material washed with variant

$R_{\text{Savinase}}$ : Reflectance of test material washed with Savinase®

$R_{\text{Blank}}$ : Reflectance of test material washed with no enzyme

10

The claimed Subtilisin 309 variants all have improved wash performance compared to Savinase® - i.e.  $P > 1$ .

The variants are divided into improvement classes designated with capital letters:

15

Class A:  $1 < P \leq 1.5$

Class B:  $1.5 < P \leq 2$

Class C:  $P > 2$

20 Table IV: Subtilisin 309 variants and improvement classes.

Improvement class	Variants
A	37.03: G97GASG + A98S+S99G+G100A+S101A 37.04: G97GAS + A98S+S99G
B	37.06: G97GAA + A98S+S99G+S101T
C	

As it can be seen from Table IV SAVINASE® variants of the invention exhibits an improvement in wash performance.

## PATENT CLAIMS

1. An isolated subtilase enzyme, having improved wash performance in a detergent, as compared to BLSAVI, having an 5 amino acid sequence which is at least 40 % identical to the amino acid sequence of the mature BLSAVI, and characterized by that at least one of the active site loops, in said isolated subtilase, is longer than the corresponding active site loop in BLSAVI, whereby such active site loops regions, in said 10 isolated subtilase, is having the minimum amino acid length as specified from the group below comprising:

- (a) the region (both of the end amino acids included) between amino acid residue from 33 to 43 is at least 12 amino acid long (i.e. at least one amino acid 15 insertion, as compared to BLSAVI);
- (b) the region (both of the end amino acids included) between amino acid residue 95 to 103 is at least 10 amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI);
- (c) the region (both of the end amino acids included) between amino acid residue 125 to 132 is at least 9 amino acids long (i.e. at least one amino acid 20 insertion, as compared to BLSAVI);
- (d) the region (both of the end amino acids included) between amino acid residue 153 to 173 is at least 22 amino acids long (i.e. at least one amino acid 25 insertion, as compared to BLSAVI);
- (e) the region (both of the end amino acids included) between amino acid residue 181 to 195 is at least 16 amino acids long (i.e. at least one amino acid 30 insertion, as compared to BLSAVI);
- (f) the region (both of the end amino acids included) between amino acid residue 202 to 204 is at least 4 amino acids long (i.e. at least one amino acid 35 insertion, as compared to BLSAVI); and
- (g) the region (both of the end amino acids included) between amino acid residue 218 to 219 is at least 3

amino acids long (i.e. at least one amino acid insertion, as compared to BLSAVI).

2. The isolated subtilase enzyme according to claim 1,  
5 wherein said subtilase enzyme is a constructed variant comprising at least one insertion of at least one amino acid within at least one of the active site loops according to claim 1.

10 3. The isolated subtilase enzyme according to claims 1 or 2, wherein at least one of said inserted amino acid residue is chosen from the group comprising: T,G,A, and S.

4. The isolated subtilase enzyme according to claims 1 or 15 2, wherein at least one of said inserted amino acid residue is chosen from the group of charged amino acid residues comprising: D,E,H,K, and R, more preferably D,E,K and R.

5. The isolated subtilase enzyme according to claims 1 or 20 2, wherein at least one of said inserted amino acid residue is chosen from the group of hydrophilic amino acid residues comprising: C,N,Q,S and T, more preferably N,Q,S and T.

6. The isolated subtilase enzyme according to claims 1 or 25 2, wherein at least one of said inserted amino acid residue is chosen from the group of small hydrophobic amino acid residues comprising: A,G and V.

7. The isolated subtilase enzyme according to claims 1 or 30 2, wherein at least one of said inserted amino acid residue is chosen from the group of large hydrophilic amino acid residues comprising: F,I,L,M,P,W and Y, more preferably F,I,L,M, and Y.

8. The isolated subtilase enzyme according to any of the 35 preceding claims, wherein said insertion, in at least one of the active site loops, comprises at least two amino acids, as compared to the corresponding active site loop in BLSAVI.

9. The isolated subtilase enzyme according to any of the preceding claims, wherein the subtilase enzyme is comprising at least one insertion, chosen from the group comprising (in BASBPN numbering) :

5 G97GASG;  
G97GAA; and  
G97GAS.

10. The isolated subtilase enzyme according to claim 9,  
10 wherein the subtilase enzyme is comprising at least one insertion/modification, chosen from the group comprising (in BASBPN numbering) :

37.03: G97GASG + A98S+S99G+G100A+S101A;  
37.06: G97GAA + A98S+S99G+S101T; and  
15 37.04: G97GAS + A98S+S99G.

11. The subtilase according to any of the preceding claims, wherein the subtilase, or if the subtilase is an variant the parent subtilase, is chosen from the sub-group I-  
20 S1.

12. The subtilase of claim 11, wherein the subtilase is chosen from the group comprising ABSS168, BASBPN, BSSDY, and BLSCAR or functional variants thereof having retained the  
25 characteristic of sub-group I-S1.

13. The subtilase according to any of claims 1-9, wherein the subtilase, or if the subtilase is an variant the parent subtilase, is chosen from the sub-group I-S2.  
30

14. The subtilase of claim 13, wherein the parent subtilase is chosen from the group comprising BLS147, BLS309, BAPB92, TVTHER AND BYSYAB or functional variants thereof having retained the characteristic of sub-group I-S2.  
35

15. The subtilase enzyme variant of any of the preceding claims, wherein said insertion(s) is/are combined with one or more modification(s) in any other position(s).

16. The subtilase variant of claim 15, wherein said modification(s) is/are combined with modification(s) in one or more of the positions 27, 36, 57, 76, 87, 97, 101, 104, 120, 123, 167, 170, 206, 218, 222, 224, 235 and 274.

17. The subtilase variant of claim 16, wherein said subtilase belongs to the I-S2 sub-group and said further change is chosen from the group comprising K27R, \*36D, S57P, 10 N76D, S87N, G97N, S101G, V104A, V104N, V104Y, H120D, N123S, Y167, R170, Q206E, N218S, M222S, M222A, T224S, K235L, and T274A.

18. The variant of claim 17 comprising any of the variants 15 S101G+V104N, S87N+S101G+V104N, K27R+V104Y+N123S+T274A, N76D+S103A+V104I or N76D+V104A, or other combinations of these mutations (V104N, S101G, K27R, V104Y, N123S, T274A, N76D, V104A), in combination with any one or more of the substitutions, deletions and/or insertions mentioned in any of 20 claims 1 to 12.

19. The subtilase variant of any of the preceding claims, wherein said modification(s) is/are combined with modification(s) in one or more of the positions 129, 131, 133 25 and 194.

20. The variant of claim 19, wherein said subtilase belongs to the I-S2 sub-group and said further modification is chosen from the group comprising P129K, P131H, A133P, A133D 30 and A194P.

21. The variant according to claim 20, wherein said further modification is chosen from the group comprising:

- 35           Y167A+R170S+A194P  
          Y167A+R170L+A194P  
          Y167A+R170N+A194P  
          Y167A+R170S+P129K  
          Y167A+R170L+P129K

Y167A+R170N+P129K  
Y167A+R170S+P131H  
Y167A+R170L+P131H  
Y167A+R170N+P131H  
5 Y167A+R170S+A133P  
Y167A+R170L+A133P  
Y167A+R170N+A133P  
Y167A+R170S+A133D  
Y167A+R170L+A133D  
10 Y167A+R170N+A133D

22. An isolated DNA sequence encoding a subtilase or a subtilase variant of any of the claims 1 to 21.

15 23. An expression vector comprising an isolated DNA sequence of claim 22.

24. A microbial host cell transformed with an expression vector of claim 23.

20 25. The microbial host of claim 24, which is a bacterium, preferably a *Bacillus*, especially *B. lenthus*.

26. The microbial host of claim 25, which is a fungus or 25 yeast, preferably a filamentous fungus, especially an *Aspergillus*.

27. A method for producing a subtilase or a subtilase variant of any of claims 1 to 21, wherein a host of any of 30 claims 23 to 26 is cultured under conditions conducive to the expression and secretion of said variant, and the variant is recovered.

28. A composition comprising a subtilase or a subtilase 35 variant according to any of claims 1 to 21.

29. The composition according to claim 28, which additionally comprises a cellulase, lipase, cutinase, oxidoreductase, another protease, or an amylase.

5 30. The composition according to claim 28 or 29, wherein the composition is a detergent composition.

31. Use of a subtilase or a subtilase variant according to any of claims 1 to 21 or an enzyme composition according to  
10 any of claims 28 to 30 in a laundry and/or a dishwash detergent.

1/4

	1	10	20		
				23	
{BASBPN}	.....AQ SVP.....	YGVSQIKAPA	LH.SQGYTGS		
{BLS147}	.....Q TVP.....	WGIFSINTQQ	AH.NRGIFGN		
{BYSYAB}	.....Q TVP.....	WGINRVQAPI	AQ.SRGFTGT		
{BAPB92}	.....AQ SVP.....	WGISRVQAPA	AH.NRGLTGS		
{BSSDY}	.....AQ TVP.....	YGIPLIKADK	VQ.AQGYKGA		
{TVTHER}	.....YTPNDPYFS SRQ.....	YGPQKIQAPQ	AW.DIAE.GS		
{BLSAVI}	.....AQ SVP.....	WGISRVQAPA	AH.NRGLTGS		
{BSISP1}	MNGEIRLIPY VTNEQIMDVN ELP.....	EGIKVIKAPE	MW.AKGVKGK		
{BSEPR}	.....SDGTDTSDN FEQ.....	WNLEPIQVKQ	AW.KAGLTGK		
{JP170}	LRGLEQIAQY ATNNNDVLYVT PKPEYEVLND	VARGIVKADV	AQNNFGLYQQ		
	30	40	50	60	
	3234				
{BASBPN}	NVKVAVIDSG IDSS.....	HPDLK..VAG	GASMVPSETN	...PFQDNNS	
{BLS147}	GARVAVLDTG IAS.....	HPDLR..IAG	GASFISSEP.	...SYHDNNNG	
{BYSYAB}	GVRVAVLDTG ISN.....	HADLR..IRG	GASFVPGEP.	...NISDGNG	
{BAPB92}	GVKVAVLDTG IST.....	HPDLN..IRG	GASFVPGEP.	...STQDGNG	
{BSSDY}	NVKVGIIDTG IAAS.....	HTDLK..VVG	GASFVSGES.	...YNTDGNG	
{TVTHER}	GAKIAIVDTG VQSN.....	HPDLAGKVVG	GWDFVDNDS.	...TPQNGNG	
{BLSAVI}	GVKVAVLDTG IST.....	HPDLN..IRG	GASFVPGEP.	...STQDGNG	
{BSISP1}	NIKVAVLDTG CDTs.....	HPDLKNQIIG	GKNFSDDGG	KEDAISDYNG	
{BSEPR}	NIKIAVIDSG ISP.....	HDDLS..IAG	GYSAVSYTS.	...SYKDDNG	
{JP170}	GQIVAVADTG LDTGRNDSSM HEAFRGKITA	LYALGRTNN.	....ANDPNG		
	70	80	90	100	110
	646566	83			
{BASBPN}	HGTHVAGTV A LNN.SIGVL	GVAPSASLYA	VKVLG.ADGS	GOYSWIING.	
{BLS147}	HGTHVAGTIA ALNN.SIGVL	GVRPSADLYA	LKVL D.RNGS	GSLASVAQG.	
{BYSYAB}	HGTQVAGTIA ALNN.SIGVL	GVAPNVDLYG	VKVLG.ASGS	GSISGIAQG.	
{BAPB92}	HGTHVAGTIA ALNN.SIGVL	GVAPNAELYA	VKVLG.ASGS	GSVSSIAQG.	
{BSSDY}	HGTHVAGTV A ALDN.TTGVL	GVAPNVSLYA	IKVLN.SSGS	GTYSAI VSG.	
{TVTHER}	HGTHCAGIAA AVTNNSTGIA	GTAPKASILA	VRVL D.NSGS	GTWTAVANG.	
{BLSAVI}	HGTHVAGTIA ALNN.SIGVL	GVAPSAELYA	VKVLG.ASGS	GSVSSIAQG.	
{BSISP1}	HGTHVAGTIA ANDS.NGGIA	GVAPEASLLI	VKVLGGENG	GQYEWIING.	
{BSEPR}	HGTHVAGIIG AKHN.GYgid	GIAPEAQIYA	VKA LD.QNGS	GDLQSLLQG.	
{JP170}	HGTHVAGSVL GNAT..N..K	GMAPQANLVF	QSIMDGGGL	GGLPANLQTL	
	120	130	140	150	
		125127	146	154155	
{BASBPN}	IEWAIANNMD VINMSLGGPS G..SAALKAA	VDKAVASG.V	VVAAAAGNEG		
{BLS147}	IEWAINNNMH IINMSLGGSTS G..SSTLELA	VNRANNAG.I	LLVGAAGNTG		
{BYSYAB}	LQWAANNGMH IANMSLGGSA G..SATMEQA	VNQATASG.V	LVVAASGNSG		
{BAPB92}	LEWAGNNGMH VANLSLGSPS P..SATLEQA	VNSATSRG.V	LVVAASGNSG		
{BSSDY}	IEWATQNGLD VINMSLGGPS G..STALKQA	VDKAYASG.I	VVAAAAGNSG		
{TVTHER}	ITYAADQGAK VISLSLGGTV G..NSGLQQA	VNYAWNKG.S	VVAAAAGNAG		
{BLSAVI}	LEWAGNNGMH VANLSLGSPS P..SATLEQA	VNSATSRG.V	LVVAASGNSG		
{BSISP1}	INYAVEEQKD IIISMSLGGPS D..VPELEEA	VKNAVKNG.V	LVVCAAGNEG		
{BSEPR}	IDWSIANRMD IVNMSLGGTT D..SKILHDA	VNKAYEQG.V	LLVAASGNNDG		
{JP170}	FSQAYSAGAR IHTNSWGAPV NGAYTTDSRN	VDDYVRKNDM	TILFAAGNEG		

Fig. 1

	160	170	180	190	
{BASBPN}	TSGS.SSTVG	YPGKYPSVIA	VGAVD.....	....SSNQ	RASFSSVG..
{BLS147}	RQG.....VN	YPARYSGVMA	VAAVD.....	....QNGQ	RASFSTYG..
{BYSYAB}	AGN.....VG	FPARYANAMA	VGATD.....	....QNNN	RATFSQYG..
{BAPB92}	AGS.....IS	YPARYANAMA	VGATD.....	....QNNN	RASFQYG..
{BSSDY}	SSGS.QNTIG	YPAKYDSVIA	VGAVD.....	....SNKN	RASFSSVG..
{TVTHER}	NTAP....N.	YPAYYSNAIA	VASTD.....	....QNDN	KSSFSTYG..
{BLSAVI}	AGS.....IS	YPARYANAMA	VGATD.....	....QNNN	RASFQYG..
{BSISP1}	DGDERTEELS	YPAAYNEVIA	VGSVS.....	....VARE	LSEFSNAN..
{BSEPR}	NGKP....VN	YPAAYSSVVA	VSATN.....	....EKNQ	LASFSTTG..
{JP170}	PGSG...TIS	APGTAKNAIT	VGATENLRPS	FGSYADNINH	VAQFSSRGPT
	200	210		220	
				219 221	225
{BASBPN}	....PELDVM	APGVSIQSTL	PGNK.....	....YGAY	NGTSMASPHV
{BLS147}	....PEIEIS	APGVNVNSTY	TGNR.....	....YVSL	SGTSMATPHV
{BYSYAB}	....AGLDIV	APGVGVQSTV	PGNG.....	....YASF	NGTSMATPHV
{BAPB92}	....AGLDIV	APGVNVQSTY	PGST.....	....YASL	NGTSMATPHV
{BSSDY}	....AELEV	APGVSVYSTY	PSNT.....	....YTSL	NGTSMASPHV
{TVTHER}	....SVVDVA	APGSWIYSTY	PTST.....	....YASL	SGTSMATPHV
{BLSAVI}	....AGLDIV	APGVNVQSTY	PGST.....	....YASL	NGTSMATPHV
{BSISP1}	....KEIDLV	APGENILSTL	PNKK.....	....YGKL	TGTSMAAPHV
{BSEPR}	....DEVEFS	APGTNITSTY	LNQY.....	....YATG	SGTSQATPHA
{JP170}	RDGRIKPDVM	APGYIILSAR	SSLAPDSSFW	ANHDSKYAYM	GGTSMATPIV
	230	240	250	260	
{BASBPN}	AGAAAALILSK	HP.....NWT	NTQVRSSLEN	TTTKLGDSF..	YYGKGLIN
{BLS147}	AGVAALVKSR	YP.....SYT	NNQIRQRINQ	TATYLGSPS..	LYGNGLVH
{BYSYAB}	AGVAALVKQK	NP.....SWS	NVQIRNHAKN	TATNLGNTT..	QFGSGLVN
{BAPB92}	AGAAAALVKQK	NP.....SWS	NVQIRNHAKN	TATSLGSTN..	LYGSGLVN
{BSSDY}	AGAAAALILSK	YP.....TLS	ASQVRNRLLS	TATNLGDSF..	YYGKGLIN
{TVTHER}	AGVAGLLASQ	.....GRS	ASNIRAAIEN	TADKISGTG..	TYWAKGRVN
{BLSAVI}	AGAAAALVKQK	NP.....SWS	NVQIRNHAKN	TATSLGSTN..	LYGSGLVN
{BSISP1}	SGALALIKSY	EEESFQRKLS	ESEVFQLIR	RTLPLDIAKT..	LAGNGFLY
{BSEPR}	AAMFALLKQR	DP.....AET	NVQLREEMRK	NIVDLGTTAGR	DOQFGYGLIO
{JP170}	AGNVAQLREH	FVKNRGVTPK	PSLLKAALIA	GAADVGLGFP	NGNQGWGRVT
	270				
{BASBPN}	VQAAAQ.				
{BLS147}	AGRATO.				
{BYSYAB}	AEAATR.				
{BAPB92}	AEAATR.				
{BSSDY}	VEAAAQ.				
{TVTHER}	AYKAVQY				
{BLSAVI}	AEAATR.				
{BSISP1}	LTAPDEL				
{BSEPR}	YKAQATD				
{JP170}	LDKSLNV				

Fig. 1 (continued)

3/4

	70	80	90	100	110
646566			83		
{BASBPN}	HGTHVAGTV A LNN. SIGVL	GVAPSASLYA	V KV LG...ADGS	GQYSWIING.	
{BLS147}	HGTHVAGTIA ALNN. SIGVL	GVRPSADLYA	LKV LD...RNGS	GSLASVAQG.	
{BYSYAB}	HGTQVAGTIA ALNN. SIGVL	GVAPNVDLYG	V KV LG...ASGS	GSISGIAQG.	
{BAPB92}	HGTHVAGTIA ALNN. SIGVL	GVAPNAELYA	V KV LG...ASGS	GSVSSIAQG.	
{BSSDY}	HGTHVAGTV A ALDN. TTGVL	GVAPNVSLYA	I KV LN...SSGS	GTYS AIVSG.	
{TVTHER}	HGTHCAGIAA AVTNNSTGIA	GTAPKASILA	VRV LD...NSGS	GTWTAVANG.	
{BLSAVI}	HGTHVAGTIA ALNN. SIGVL	GVAPS AELYA	V KV LG...ASGS	GSVSSIAQG.	
{BSISP1}	HGTHVAGTIA ANDS. NGGIA	GVAPEASLLI	V KV LGG..ENGS	GQYEWIING.	
{BSEPR}	HGTHVAGIIG AKHN. GYGID	GI APEAQIYA	V KA LD...QNGS	GDLQSLLQG.	
{JP170}	HGTHVAGSVL GNAT...N..K	GMA PQANLVF	QSIMDS..GGGL	GGLPANLQTL	
{37.03}			A V KV LGAS GSGAA	GSVSSI	
{37.04}			A V KV LGAS. SGGS	GSVSSI	
{37.06}			A V KV LGAA. SGGT	GSVSSI	

Fig. 2

4/4




Fig. 3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00496

## A. CLASSIFICATION OF SUBJECT MATTER

**IPC6: C12N 9/54, C11D 3/386**

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

**IPC6: C12N**

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

**SE,DK,FI,NO classes as above**

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**WPI, CA, BIOSIS**

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 9628566 A2 (THE PROCTER & GAMBLE COMPANY), 19 Sept 1996 (19.09.96), page 4, line 1 - line 11  --	1-31
A	WO 9634935 A2 (UNILEVER N.V.), 7 November 1996 (07.11.96), page 15, line 4 - line 5, figure 2, claims 8,9,11  --	1-31
A	EP 0405901 A1 (UNILEVER PLC), 2 January 1991 (02.01.91), page 6, line 30 - line 43, claim 1  --	1-31

 Further documents are listed in the continuation of Box C. See patent family annex.

- \* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
24 February 1999	26-02-1999
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86	Authorized officer  Yvonne Siösteen Telephone No. + 46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 98/00496

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>Book author/Editor: Clark D S; Estell D A: Eds, Annals New York academy of sciences, 672, 1992, Thomas P. Graycar et al: "Altering the Proteolytic Activity of Subtilisin through Protein Engineering", see conclusion p 76-78</p> <p>--</p> <p>-----</p>	1-31

## INTERNATIONAL SEARCH REPORT

Information on patent family members

02/02/99

International application No.

PCT/DK 98/00496

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9628566 A2	19/09/96	AU 4868896 A		02/10/96
		CA 2214348 A		19/09/96
		CN 1183119 A		27/05/98
		CZ 9702793 A		12/11/97
		EP 0813596 A		29/12/97
		HU 9800765 A		28/07/98
		IL 117266 D		00/00/00
<hr/>				
WO 9634935 A2	07/11/96	AU 5646596 A		21/11/96
		CA 2217162 A		07/11/96
		CZ 9703497 A		15/04/98
		EP 0827531 A		11/03/98
		PL 323188 A		16/03/98
		SK 146797 A		04/03/98
		US 5837517 A		17/11/98
<hr/>				
EP 0405901 A1	02/01/91	CA 2034486 A		27/12/90
		JP 4500385 T		23/01/92
		US 5665587 A		09/09/97
		WO 9100334 A		10/01/91
		EP 0405902 A		02/01/91
		JP 4500384 T		23/01/92
		WO 9100335 A		10/01/91
<hr/>				